Program List

All presentations are listed on this page. You can view the details of the presentations that interest you and bookmark them. You can log in to the registration system to view or manage the presentations and sessions you’ve bookmarked.
Program at a Glance Program List Search with Title
Program Book (PDF) Conference Photos (available until March 6, 2025)
Plenary Session
Keynote Presentation
Symposium
Concurrent Contributed Papers
Poster Session
Educational Session
Plenary Session 1
Recent development of case-only studies in Asia-Pacific region
Recent development of case-only studies in Asia-Pacific region
Details
Date
October Sat 12, 2024 18:15 - 19:15
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
Nobuhiro Ooba(Nihon University)
Kinwei Chan(TriNetX LLC)
PL1-1 How to detect and remove biases specific to case-crossover studies
PL1-1 How to detect and remove biases specific to case-crossover studies
Speaker
Kiyoshi Kubota(NPO Drug Safety Research Unit Japan)
PL1-2 Co-presenter: Self-controlled case series: the best thing since sliced bread?
PL1-2 Co-presenter: Self-controlled case series: the best thing since sliced bread?
Speaker
Angel Wong(London School of Hygiene and Tropical Medicine)
Plenary Session 3
Translating pharmacoepidemiology research into real-world practice in the Asia-Pacific region
Translating pharmacoepidemiology research into real-world practice in the Asia-Pacific region
Details
Date
October Mon 14, 2024 10:15 - 11:15
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
Frank May(RGH Pharmacy Consulting Services)
PL3 Translating pharmacoepidemiology research into real-world practice in the Asia-Pacific region
PL3 Translating pharmacoepidemiology research into real-world practice in the Asia-Pacific region
Speaker
Yea-Huei Yang-Kao
Plenary Session 2
Keynote Presentation
Keynote Presentation
Details
Date
October Sun 13, 2024 09:00 - 10:00
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
Soko Setoguchi(Rutgers University)
Hiraku Kumamaru(The University of Tokyo)
Keynote Causal estimands: Should we ask different causal questions in randomized trials and in the observational studies that emulate them?
Keynote Causal estimands: Should we ask different causal questions in randomized trials and in the observational studies that emulate them?
Speaker
Miguel Hernan
Symposium 1
Navigating Oncology RWD Landscape in Asia Pacific: Access, Collaboration, & Future Directions
Navigating Oncology RWD Landscape in Asia Pacific: Access, Collaboration, & Future Directions
Details
Date
October Sun 13, 2024 10:30 - 12:00
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
SY1-1 　
SY1-1 　
Speaker
Kiyoshi Kubota(NPO Drug Safety Research Unit Japan)
SY1-2 　
SY1-2 　
Speaker
Edward Chia-Cheng Lai
SY1-3 　
SY1-3 　
Speaker
Yvonne Lee(IQVIA Solutions Asia)
Symposium 2
Leveraging EHRs in Japan Pharma Industry: Current Status, Issues, & Futures
Leveraging EHRs in Japan Pharma Industry: Current Status, Issues, & Futures
Details
Date
October Sun 13, 2024 10:30 - 12:00
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Room 2)
Chairperson
SY2-1 　
SY2-1 　
Speaker
Takayuki Imaeda
SY2-2 　
SY2-2 　
Speaker
Yasunari Sadatsuki
SY2-3 　
SY2-3 　
Speaker
Kanae Togo
SY2-4 　
SY2-4 　
Speaker
Seitaro Yoshida
Symposium 3
Deprescription Dynamics: Insights & Strategies for Optimizing Med mgmt in Healthcare Landscapes
Deprescription Dynamics: Insights & Strategies for Optimizing Med mgmt in Healthcare Landscapes
Details
Date
October Sun 13, 2024 10:30 - 12:00
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Room 3)
Chairperson
SY3-1 　
SY3-1 　
Speaker
AMAL ANAND(Rutgers University)
SY3-2
SY3-2
Speaker
Atiqulla Shariff(JSS College of Pharmacy, Mysuru.)
SY3-3 　
SY3-3 　
Speaker
Shilpa Palaksha(JSS College of Pharmacy, JSS AHER, Mysuru)
SY3-4 　
SY3-4 　
Speaker
Jisha Myalil Lucca(Gulf medical University)
Symposium 4
Evaluation of vaccination policy
Evaluation of vaccination policy
Details
Date
October Sun 13, 2024 10:30 - 12:00
Room
Faculty of Medicine Bldg. 1 (Venue M1-1F)(The University of Tokyo (Hongo Campus) Room 4)
Chairperson
SY4-1 　
SY4-1 　
Speaker
Simon Bell
SY4-2 　
SY4-2 　
Speaker
Ching-Lan Cheng
SY4-3 　
SY4-3 　
Speaker
George Okoli(The University of Hong Kong)
SY4-4 　
SY4-4 　
Speaker
Grace Wangge(Monash University, Indonesia)
Symposium 5
Use of Real-world data for regulatory decision making: the value of collaborations
Use of Real-world data for regulatory decision making: the value of collaborations
Details
Date
October Sun 13, 2024 14:45 - 16:15
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
SY5-1 　
SY5-1 　
Speaker
Kristian Filion
SY5-2 　
SY5-2 　
Speaker
Helga Gardarsdottir
SY5-3 　
SY5-3 　
Speaker
Olaf Klungel
SY5-4 　
SY5-4 　
Speaker
Edward Chia-Cheng Lai
SY5-5 　
SY5-5 　
Speaker
Kenneth Man
SY5-6 　
SY5-6 　
Speaker
Ju-Young Shin
Symposium 6
Student Initiatives in Training Newcomers in Pharmacoepi. in Non-native English-Speaking Countries
Student Initiatives in Training Newcomers in Pharmacoepi. in Non-native English-Speaking Countries
Details
Date
October Sun 13, 2024 14:45 - 16:15
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Room 2)
Chairperson
SY6-1 　
SY6-1 　
Speaker
Min Fan(University of Hong Kong)
SY6-2 　
SY6-2 　
Speaker
Shiori Nishimura(The University of Tokyo Graduate School of Medicine)
SY6-3 　
SY6-3 　
Speaker
Mita Restinia
SY6-4 　
SY6-4 　
Speaker
Daniel Hsiang-Te Tsai(National Cheng Kung University)
Symposium 7
Govt-Ind.-Acad. Collab. in Post-mkt Outcome Val. Studies: Design, Challenges, & Future Opportunities
Govt-Ind.-Acad. Collab. in Post-mkt Outcome Val. Studies: Design, Challenges, & Future Opportunities
Details
Date
October Sun 13, 2024 14:45 - 16:15
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Room 3)
Chairperson
SY7-1 　
SY7-1 　
Speaker
Yujing Huang
SY7-2 　
SY7-2 　
Speaker
Kataoka Kensuke
SY7-3 　
SY7-3 　
Speaker
Hotaka Maruyama
SY7-4 　
SY7-4 　
Speaker
Mari Matsui
SY7-5 　
SY7-5 　
Speaker
Naoki Nakashima
Symposium 8
Real-World Data in Japan: Overview & Exs. from JSPE Medical and Healthcare DB. Utilization Committee
Real-World Data in Japan: Overview & Exs. from JSPE Medical and Healthcare DB. Utilization Committee
Details
Date
October Sun 13, 2024 14:45 - 16:15
Room
Faculty of Medicine Bldg. 1 (Venue M1-1F)(The University of Tokyo (Hongo Campus) Room 4)
Chairperson
SY8-1 　
SY8-1 　
Speaker
Shinobu Imai
SY8-2
SY8-2
Speaker
Akihiro Nakajima(Teijin Pharma Limited)
SY8-3 　
SY8-3 　
Speaker
Ryo WATANABE
SY8-4 　
SY8-4 　
Speaker
Miho Ishimaru
SY8-5 　
SY8-5 　
Speaker
Maki Komamine
Symposium 9
3 Approaches to Conduct RWD Studies Across Mult. HC Sys.: Common Research Q, Proc., & Data Model
3 Approaches to Conduct RWD Studies Across Mult. HC Sys.: Common Research Q, Proc., & Data Model
Details
Date
October Mon 14, 2024 08:30 - 10:00
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
SY9-1 　
SY9-1 　
Speaker
Suzu Chia-Hsien Chang
SY9-2 　
SY9-2 　
Speaker
Ching Lung Cheung
SY9-3 　
SY9-3 　
Speaker
Jeffrey Lange
SY9-4 　
SY9-4 　
Speaker
Hojoon Lee
SY9-5 　
SY9-5 　
Speaker
Chin-Yao Shen
Symposium 10
Medical Device Epidemiology in Asia: Examples and Challenges
Medical Device Epidemiology in Asia: Examples and Challenges
Details
Date
October Mon 14, 2024 08:30 - 10:00
Room
South Clinical Research Building (3F)(The University of Tokyo (Hongo Campus) Tetsumon Clinical Lecture Hall)
Chairperson
SY10-1 　
SY10-1 　
Speaker
Hiraku Kumamaru
SY10-2 　
SY10-2 　
Speaker
Mary Beth Ritchey
SY10-3 　
SY10-3 　
Speaker
Hironobu Tokumasu
SY10-4 　
SY10-4 　
Speaker
Yongjing Zhang
Symposium 11
Early-career pharmacoepidemiologists: perspectives and progress from Asia
Early-career pharmacoepidemiologists: perspectives and progress from Asia
Details
Date
October Mon 14, 2024 08:30 - 10:00
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Room 3)
Chairperson
SY11-1 　
SY11-1 　
Speaker
Toshiki Fukasawa
SY11-2 　
SY11-2 　
Speaker
Na-Young Jeong(Ewha Womans University)
SY11-3
SY11-3
Speaker
Jui Wang(National Taiwan University)
SY11-4 　
SY11-4 　
Speaker
Eric Yuk Fai Wan
SY11-5 　
SY11-5 　
Speaker
Thi Hong Nhung Trinh(University of Oslo)
Symposium 12
Leveraging regulatory pharmacoepidemiology for informed decision making in Asia
Leveraging regulatory pharmacoepidemiology for informed decision making in Asia
Details
Date
October Mon 14, 2024 14:00 - 15:30
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
SY12-1 　
SY12-1 　
Speaker
Lih-jiuan Hsu
SY12-2 　
SY12-2 　
Speaker
Kazuhiro Kajiyama
SY12-3 　
SY12-3 　
Speaker
In-sook Park
SY12-4 　
SY12-4 　
Speaker
YOSHIAKI UYAMA
Symposium 13
From Asia to the World – Engaging in the ISPE Strategic Plan 2024-2029
From Asia to the World – Engaging in the ISPE Strategic Plan 2024-2029
Details
Date
October Mon 14, 2024 14:00 - 15:30
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Room 2)
Chairperson
SY13-1 　
SY13-1 　
Speaker
Yea-Huei Yang-Kao
SY13-2 　
SY13-2 　
Speaker
Hiraku Kumamaru
SY13-3 　
SY13-3 　
Speaker
Mary Beth Ritchey
Symposium 14
Climate Change and Pharmacoepidemiology in Asia
Climate Change and Pharmacoepidemiology in Asia
Details
Date
October Mon 14, 2024 14:00 - 15:30
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Room 3)
Chairperson
SY14-1 　
SY14-1 　
Speaker
Masahiro Hashizume(University of Tokyo)
SY14-2 　
SY14-2 　
Speaker
Soko Setoguchi(Ruthers University)
SY14-3 　
SY14-3 　
Speaker
Harish Phuleria(Indian Institute of Technology Bombay)
SY14-4 　
SY14-4 　
Speaker
Benjamin Bates(Rutgers University )
SY14-5 　
SY14-5 　
Speaker
Shu Ping Huang(Changhua Christian Hospital)
Symposium 15
From Blueprint to Reality: Dev., Conv., & App. in Common Data Model Among Asia-Pacific Databases
From Blueprint to Reality: Dev., Conv., & App. in Common Data Model Among Asia-Pacific Databases
Details
Date
October Mon 14, 2024 14:00 - 15:30
Room
Faculty of Medicine Bldg. 1 (Venue M1-1F)(The University of Tokyo (Hongo Campus) Room 4)
Chairperson
SY15-1 　
SY15-1 　
Speaker
Celine Chui
SY15-2 　
SY15-2 　
Speaker
Bin Hong(Sungkyunkwan University)
SY15-3 　
SY15-3 　
Speaker
Brian Li(National Cheng Kung University)
SY15-4 　
SY15-4 　
Speaker
Hsun-Yin Liang
SY15-5 　
SY15-5 　
Speaker
Chin-Yao Shen
Symposium 16
Maternal and perinatal health studies using Real-World Data
Maternal and perinatal health studies using Real-World Data
Details
Date
October Mon 14, 2024 14:00 - 15:30
Room
Faculty of Medicine Bldg. 1 (Venue M1-3F)(The University of Tokyo (Hongo Campus) Room 5)
Chairperson
SY16-1 　
SY16-1 　
Speaker
Adrienne Chan(The University of Hong Kong)
SY16-2 　
SY16-2 　
Speaker
Kenneth Man
SY16-3 　
SY16-3 　
Speaker
Ju-Young Shin
SY16-4 　
SY16-4 　
Speaker
Avery Shuei-He Yang(National Cheng-Kung University)
Methods
Details
Date
October Sun 13, 2024 13:00 - 14:30
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
O100 Research status of applying common data model in pharmacoepidemiology: a systematic review
O100 Research status of applying common data model in pharmacoepidemiology: a systematic review
Speaker
Meng Zhang(Peking University)
O101 The utility of event-specific methods in causality assessment of drug-adverse reaction
O101 The utility of event-specific methods in causality assessment of drug-adverse reaction
Speaker
Miki Ohta(Clinical Research Promotion Center)
O102 Performance of Matching with Oversample and Replacement Strategy for Imbalanced Real-world Dataset.
O102 Performance of Matching with Oversample and Replacement Strategy for Imbalanced Real-world Dataset.
Speaker
Tanavij Pannoi(Walailak University)
O103 Evaluation of Logistic Regression Model for Analyzing Pooled Observational Epidemiological Databases
O103 Evaluation of Logistic Regression Model for Analyzing Pooled Observational Epidemiological Databases
Speaker
Md Jamal Uddin(Shahjalal University of Science and Technology)
O104 Synchronization of time zero in pharmacoepidemiology studies using target trial emulation approach
O104 Synchronization of time zero in pharmacoepidemiology studies using target trial emulation approach
Speaker
Tengfei Lin(Chinese Academy of Sciences)
O105 Baseline Adjustment to Compare Post-marketing Surveillance Study and Randomized Clinical Trial
O105 Baseline Adjustment to Compare Post-marketing Surveillance Study and Randomized Clinical Trial
Speaker
Richuan Zheng(Janssen Pharmaceutical K. K.)
COPD / Asthma
Details
Date
October Sun 13, 2024 13:00 - 14:30
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Room 2)
Chairperson
O106 Comparative Cardiovascular Safety of Fixed-dose Combinations of LABA/LAMA/ICS versus LABA/ICS in COPD
O106 Comparative Cardiovascular Safety of Fixed-dose Combinations of LABA/LAMA/ICS versus LABA/ICS in COPD
Speaker
Marie Lu(National Yang Ming Chiao Tung University)
O107 Cost-effectiveness of triple therapy compared to dual therapy in chronic obstructive pulmonary disease: A systematic review and meta-analysis
O107 Cost-effectiveness of triple therapy compared to dual therapy in chronic obstructive pulmonary disease: A systematic review and meta-analysis
Speaker
Keerthi Raj(National Institute of Pharmaceutical Education and research)
O108 Comparative effectiveness of inhaled corticosteroid in combination therapy for patients with chronic-obstructive-pulmonary-disease
O108 Comparative effectiveness of inhaled corticosteroid in combination therapy for patients with chronic-obstructive-pulmonary-disease
Speaker
XiaoYan Ni(Southeast university)
O109 Combination of chinese and western medications among chronic obstructive pulmonary disease patients
O109 Combination of chinese and western medications among chronic obstructive pulmonary disease patients
Speaker
Ming-Chia Lee(New Taipei City Hospital)
O110 Trends of pneumococcal vaccination coverage among U.S. chronic obstructive pulmonary disease populations
O110 Trends of pneumococcal vaccination coverage among U.S. chronic obstructive pulmonary disease populations
Speaker
Yan Ning Zeng(Taipei Medical University)
O111 Antidiabetic agents and asthma exacerbation in patients with asthma and diabetes
O111 Antidiabetic agents and asthma exacerbation in patients with asthma and diabetes
Speaker
Kevin Yi-Chen Liao(National Cheng Kung University)
Cardiovascular 1
Details
Date
October Sun 13, 2024 13:00 - 14:30
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Room 3)
Chairperson
O112 Validating a Cox-Regression Model to Predict Mortality in HFrEF Patients Using Real-World-Data
O112 Validating a Cox-Regression Model to Predict Mortality in HFrEF Patients Using Real-World-Data
Speaker
Yasmin Elsobky(ALNAS Hospital)
O113 Superior Effectiveness of Prasugrel over Ticagrelor in Individuals with Acute Coronary Syndrome
O113 Superior Effectiveness of Prasugrel over Ticagrelor in Individuals with Acute Coronary Syndrome
Speaker
Nils Kruger(Harvard Medical School)
O114 Aspirin versus clopidogrel on incident type 2 diabetes in patients with CVD
O114 Aspirin versus clopidogrel on incident type 2 diabetes in patients with CVD
Speaker
Xi Xiong(The University of Hong Kong)
O115 Potential interactions between digoxin and direct oral anticoagulants: cohort & case-crossover designs
O115 Potential interactions between digoxin and direct oral anticoagulants: cohort & case-crossover designs
Speaker
Angel Wong(London School of Hygiene and Tropical Medicine)
O116 Anticoagulant Discontinuation After Minor Bleed and Stroke Risk Among Atrial Fibrillation Patients
O116 Anticoagulant Discontinuation After Minor Bleed and Stroke Risk Among Atrial Fibrillation Patients
Speaker
Shiori Nishimura(The University of Tokyo Graduate School of Medicine)
O117 Fish oil supplementation, Life’s Essential 8, and cardiovascular mortality in diabetic patients
O117 Fish oil supplementation, Life’s Essential 8, and cardiovascular mortality in diabetic patients
Speaker
Rong Hua(The Chinese University of Hong Kong)
Infectious Disease&Antibiotics
Details
Date
October Sun 13, 2024 13:00 - 14:30
Room
Faculty of Medicine Bldg. 1 (Venue M1-1F)(The University of Tokyo (Hongo Campus) Room 4)
Chairperson
O118 Risk of macrolides and fluoroquinolones on fatal arrhythmia: a nested case-control study
O118 Risk of macrolides and fluoroquinolones on fatal arrhythmia: a nested case-control study
Speaker
Reo Shibata(Yokohama City University)
O119 Antibiotic De-escalation via the use of Novel Metric among Cancer Patients: A DASC-based Approach
O119 Antibiotic De-escalation via the use of Novel Metric among Cancer Patients: A DASC-based Approach
Speaker
DEEPTHI AVVARU(Kasturba Medical College)
O120 Clinical and Economic Impact of Clinical Pharmacist-Steered Handshake Antibiotic Stewardship in Surgery
O120 Clinical and Economic Impact of Clinical Pharmacist-Steered Handshake Antibiotic Stewardship in Surgery
Speaker
Ann Kuruvilla(JSS College of Pharmacy)
O121 Prevalence of MALDI-TOF MS for patients with bacteremia using Japanese administrative claims database from FY 2018 to 2020
O121 Prevalence of MALDI-TOF MS for patients with bacteremia using Japanese administrative claims database from FY 2018 to 2020
Speaker
Shoji Tomokazu(Department of Pharmacy , University of Yamanashi Hospital)
O122 Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review
O122 Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review
Speaker
Joseph Blais(The University of Hong Kong)
O123 Risk factors for S.aureus and MRSA carriage in children: a case-control study
O123 Risk factors for S.aureus and MRSA carriage in children: a case-control study
Speaker
TSZ YING NATALIE TSIE(The University of Hong Kong)
Diabetes
Details
Date
October Sun 13, 2024 16:45 - 18:15
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
O124 SGLT2 Inhibitors and Risk of CKD-MBD in Patients with T2D and CKD
O124 SGLT2 Inhibitors and Risk of CKD-MBD in Patients with T2D and CKD
Speaker
Shih-Chieh Shao(Keelung Chang Gung Memorial Hospital)
O125 Trends in Antidiabetic Medication Use among Patients with Diabetes in the U.S.
O125 Trends in Antidiabetic Medication Use among Patients with Diabetes in the U.S.
Speaker
Yu Chien Chen(Taipei Medical University)
O126 Glycemic Variability and Persistent Acute Kidney Injury: Multicenter Study with External Validation
O126 Glycemic Variability and Persistent Acute Kidney Injury: Multicenter Study with External Validation
Speaker
Siyu Kong(China Pharmaceutical University)
O127 Comparison of Suicidal-Related Behaviors Between GLP-1RAs and DPP4 Inhibitors in Taiwan
O127 Comparison of Suicidal-Related Behaviors Between GLP-1RAs and DPP4 Inhibitors in Taiwan
Speaker
Chris Tzu-Ting Su(National Cheng Kung University)
O128 Comparing cardio-hepatic benefits of GLP1rA and pioglitazone: A target trial emulation study
O128 Comparing cardio-hepatic benefits of GLP1rA and pioglitazone: A target trial emulation study
Speaker
Lanlan Li(University of Hong Kong)
O129 Associations between Newer Glucose-Lowering Drugs and Cognitive Impairment in Adults with Diabetes
O129 Associations between Newer Glucose-Lowering Drugs and Cognitive Impairment in Adults with Diabetes
Speaker
Piaopiao Li(University of Florida)
Eyes & Kidney
Details
Date
October Sun 13, 2024 16:45 - 18:15
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Room 2)
Chairperson
O130 Ophthalmic complications of platinum-based chemotherapy: Insights from disproportionality analysis and systematic review
O130 Ophthalmic complications of platinum-based chemotherapy: Insights from disproportionality analysis and systematic review
Speaker
Hasik PN(National Institute of Pharmaceutical Education and Research)
O131 Comparative Effectiveness Between Topical alpha-2 Agonist, Carbonic Anhydrase Inhibitor and Prostaglandin Analog combination therapy for Second-Line Glaucoma Treatment?
O131 Comparative Effectiveness Between Topical alpha-2 Agonist, Carbonic Anhydrase Inhibitor and Prostaglandin Analog combination therapy for Second-Line Glaucoma Treatment?
Speaker
Avery Shuei-He Yang(National Cheng-Kung University)
O132 Comparative Glaucoma Risks Associated with Topiramate and Phenytoin: A Comparative Cohort Study
O132 Comparative Glaucoma Risks Associated with Topiramate and Phenytoin: A Comparative Cohort Study
Speaker
Wan-Ju Annabelle LEE(Chi Mei Medical Center)
O133 Glaucoma eye drops and risk of asthma attacks: A target trial emulation
O133 Glaucoma eye drops and risk of asthma attacks: A target trial emulation
Speaker
Yuto Kono(Yokohama City University)
O134 Acute Kidney Disease Risk and Postoperative Glycemic Variability After Cardiac Surgery
O134 Acute Kidney Disease Risk and Postoperative Glycemic Variability After Cardiac Surgery
Speaker
Siyu Kong(China Pharmaceutical University)
O135 Validation of Kidney Failure Risk Equation for Renal Anemia in Asians
O135 Validation of Kidney Failure Risk Equation for Renal Anemia in Asians
Speaker
Yuqing Bao(China Pharmaceutical University)
Vaccination
Details
Date
October Sun 13, 2024 16:45 - 18:15
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Room 3)
Chairperson
O136 Risk of Polymyalgia Rheumatica Following COVID-19 Vaccination in South Korea: SCCS study
O136 Risk of Polymyalgia Rheumatica Following COVID-19 Vaccination in South Korea: SCCS study
Speaker
HyunJoo Lim(Sungkyunkwan University)
O137 Gender Differences in Adverse Events Following COVID-19 Vaccination in South Korea
O137 Gender Differences in Adverse Events Following COVID-19 Vaccination in South Korea
Speaker
Jeong Ah Kim(Ewha Womans University)
O138 Sequential analysis of COVID-19 vaccine safety in Korea
O138 Sequential analysis of COVID-19 vaccine safety in Korea
Speaker
Na-Young Jeong(Ewha Womans University)
O139 Global burden of vaccine-induced thrombotic thrombocytopenia: analysis of the international pharmacovigilance database
O139 Global burden of vaccine-induced thrombotic thrombocytopenia: analysis of the international pharmacovigilance database
Speaker
Yejun Son(Kyung Hee University College of Medicine)
O140 The risk of acute gastroenteritis following co-administration of rotavirus vaccine
O140 The risk of acute gastroenteritis following co-administration of rotavirus vaccine
Speaker
Hui-Eon Lee(Ewha Womans University)
O141 Gastroenteritis hospitalizations before and after rotavirus vaccine: descriptive study using nationwide database
O141 Gastroenteritis hospitalizations before and after rotavirus vaccine: descriptive study using nationwide database
Speaker
Takanori Yanai(Kyoto University Graduate School of Medicine and Public Health)
Opioids / Signal Detection
Details
Date
October Sun 13, 2024 16:45 - 18:15
Room
Faculty of Medicine Bldg. 1 (Venue M1-1F)(The University of Tokyo (Hongo Campus) Room 4)
Chairperson
O142 High-risk opioid prescribing and persistent opioid use in Australian workers with injuries
O142 High-risk opioid prescribing and persistent opioid use in Australian workers with injuries
Speaker
Yonas Tefera(Monash University)
O143 Association of benzodiazepines and mortality among patients with non-opioid substance use disorder
O143 Association of benzodiazepines and mortality among patients with non-opioid substance use disorder
Speaker
Brian Li(National Cheng Kung University)
O144 Prevalence and risk factors of cannabis use after legalization in rural communities
O144 Prevalence and risk factors of cannabis use after legalization in rural communities
Speaker
Natthaya Chaomuang(University of Phayao)
O145 Psychotropic medicine utilisation in Australian workers with back and neck injuries
O145 Psychotropic medicine utilisation in Australian workers with back and neck injuries
Speaker
Yonas Tefera(Monash University)
O146 Regular opioid use of different potency and dementia risk and neuroimaging outcomes
O146 Regular opioid use of different potency and dementia risk and neuroimaging outcomes
Speaker
Tengfei Lin(Chinese Academy of Sciences)
O147 Identifying Safety Signals for Adverse Events Causing Mortality Due to Ferric Carboxymaltose
O147 Identifying Safety Signals for Adverse Events Causing Mortality Due to Ferric Carboxymaltose
Speaker
RATHOD MAHESH(National institute of pharmaceutical education and research)
Geriatric
Details
Date
October Mon 14, 2024 08:30 - 10:00
Room
Faculty of Medicine Bldg. 1 (Venue M1-1F)(The University of Tokyo (Hongo Campus) Room 4)
Chairperson
O200 Association between Anticholinergic burden and risk of Fall and Fracture: Case-Case-Time-Control Study (Rising Star Awardee)
O200 Association between Anticholinergic burden and risk of Fall and Fracture: Case-Case-Time-Control Study (Rising Star Awardee)
Speaker
Tzu-Ming Chuang(Population Health Data Center, National Cheng Kung University)
O201 Association between Recently Elevated Anticholinergic Burden and Urinary Retention: A Case-case-time-control Study
O201 Association between Recently Elevated Anticholinergic Burden and Urinary Retention: A Case-case-time-control Study
Speaker
Daniel Hsiang-Te Tsai(National Cheng Kung University)
O202 Associations Between Polypharmacy, Inflammatory Markers and biological aging among US Older Adults
O202 Associations Between Polypharmacy, Inflammatory Markers and biological aging among US Older Adults
Speaker
Kai Wei(Guizhou Provincial People's Hospital)
O203 Predicting Long-Term Mortality in Elderly Using Shizuoka Hip Fracture Prognostic Score: SHiPS
O203 Predicting Long-Term Mortality in Elderly Using Shizuoka Hip Fracture Prognostic Score: SHiPS
Speaker
Emi Ohata(4DIN Ltd.)
O204 Sedative and anticholinergic medication use in older Australians with dementia
O204 Sedative and anticholinergic medication use in older Australians with dementia
Speaker
Edwin Tan(The University of Sydney)
O205 Calcium Channel Blockers and Selective Serotonin Reuptake Inhibitors Use and Fracture Risk
O205 Calcium Channel Blockers and Selective Serotonin Reuptake Inhibitors Use and Fracture Risk
Speaker
Haesuk Park(University of Florida)
Cancer
Details
Date
October Mon 14, 2024 08:30 - 10:00
Room
Faculty of Medicine Bldg. 1 (Venue M1-3F)(The University of Tokyo (Hongo Campus) Room 5)
Chairperson
O206 Utility of electronic medical record databases for oncology pharmacoepidemiologic studies in Japan
O206 Utility of electronic medical record databases for oncology pharmacoepidemiologic studies in Japan
Speaker
Kiyoshi Kubota(NPO Drug Safety Research Unit Japan)
O207 Heavy Metal Contamination in Drinking Water Increases Gallbladder Cancer Risk in India
O207 Heavy Metal Contamination in Drinking Water Increases Gallbladder Cancer Risk in India
Speaker
Christy Thomas(National Institute of Pharmaceutical Education and Research)
O208 Treatment patterns and outcomes of EGFR exon20ins mutated NSCLC patients in Taiwan
O208 Treatment patterns and outcomes of EGFR exon20ins mutated NSCLC patients in Taiwan
Speaker
Kai-Cheng Chang(LinKou Chang Gung Memorial Hospital)
O209 Risk of lung cancer with concomitant use of ACEi and DPP4i
O209 Risk of lung cancer with concomitant use of ACEi and DPP4i
Speaker
Bin Hong(Sungkyunkwan University)
O210 Treatment modalities for primary head and neck cancer in Japan
O210 Treatment modalities for primary head and neck cancer in Japan
Speaker
Grace Hui-Min Wu(Johnson & Johnson)
O211 Occurrence of Adverse Drug Reactions in Chemotherapy Patients: A Cross-sectional Study
O211 Occurrence of Adverse Drug Reactions in Chemotherapy Patients: A Cross-sectional Study
Speaker
Zuha Shyma(Manipal College of Pharmaceutical Science)
Cardiovascular 2
Details
Date
October Mon 14, 2024 11:30 - 13:00
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
O212 Disease burden and treatment patterns of atherosclerotic cardiovascular diseases in Hong Kong
O212 Disease burden and treatment patterns of atherosclerotic cardiovascular diseases in Hong Kong
Speaker
Yu Yang(The university of Hong Kong)
O213 Associations of biological aging with intraoperative hypotension during major surgery
O213 Associations of biological aging with intraoperative hypotension during major surgery
Speaker
Xuan Yin(China Pharmaceutical University)
O214 Influenza vaccines reduce hospitalized cardiovascular complications in Taiwan elderly: a nationwide study
O214 Influenza vaccines reduce hospitalized cardiovascular complications in Taiwan elderly: a nationwide study
Speaker
Zi-Yang Peng(National Cheng Kung University)
O215 Exploring the cardiometabolic impact of antipsychotics: real-world evidence from Australia
O215 Exploring the cardiometabolic impact of antipsychotics: real-world evidence from Australia
Speaker
Ramya Padmavathy Radha Krishnan(University of Sydney)
O216 Trends in the use of sodium-glucose cotransporter 2 inhibitors following hospitalisation with heart failure, New South Wales, Australia
O216 Trends in the use of sodium-glucose cotransporter 2 inhibitors following hospitalisation with heart failure, New South Wales, Australia
Speaker
Jialing Lin(University of New South Wales)
O217 Low-dose versus standard-dose prasugrel in East Asians with acute coronary syndrome: a matching-adjusted indirect comparison using real-world data
O217 Low-dose versus standard-dose prasugrel in East Asians with acute coronary syndrome: a matching-adjusted indirect comparison using real-world data
Speaker
You-Shin Tsai(National Taiwan University)
Cost Effect./Economic Evals.
Details
Date
October Mon 14, 2024 11:30 - 13:00
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Room 2)
Chairperson
O218 Real-world cost-effectiveness study of first and third generation EGFR-TKIs for advanced NSCLC
O218 Real-world cost-effectiveness study of first and third generation EGFR-TKIs for advanced NSCLC
Speaker
Avinash Khadela(L. M. College of Pharmacy)
O219 Impact of Price Changes on Economic Burden of Anemia Treatment in CKD
O219 Impact of Price Changes on Economic Burden of Anemia Treatment in CKD
Speaker
Yuqing Bao(China Pharmaceutical University)
O220 Cost-effectiveness analysis of combinatorial pharmacogenomic-guided treatment for major depression
O220 Cost-effectiveness analysis of combinatorial pharmacogenomic-guided treatment for major depression
Speaker
Dina Abushanab(Monash University)
O221 Productivity Burden of Cardiovascular Disease in Diabetes and Impact of Health Interventions
O221 Productivity Burden of Cardiovascular Disease in Diabetes and Impact of Health Interventions
Speaker
Dina Abushanab(Monash University)
O222 Cost-effectiveness of universal screening for Lynch syndrome among colorectal cancer patients in Vietnam
O222 Cost-effectiveness of universal screening for Lynch syndrome among colorectal cancer patients in Vietnam
Speaker
Cong Bang Huynh(University of Medicine and Pharmacy at Ho Chi Minh City)
O223 Assessing Burden of Chronic Diseases on Health-Related Quality of Life in Taiwan
O223 Assessing Burden of Chronic Diseases on Health-Related Quality of Life in Taiwan
Speaker
Chia-Chen Hung(National Taiwan University)
Prenatal & Pregnancy
Details
Date
October Mon 14, 2024 11:30 - 13:00
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Room 3)
Chairperson
O224 Prenatal and infant antibiotic exposure linked to child neuropsychiatric disorder risk
O224 Prenatal and infant antibiotic exposure linked to child neuropsychiatric disorder risk
Speaker
Jaeyu Park(Kyung Hee University)
O225 A national population study of preterm birth following COVID-19 vaccination during pregnancy
O225 A national population study of preterm birth following COVID-19 vaccination during pregnancy
Speaker
Erdenetuya Bolormaa(Korea University College of Medicine)
O226 Pregnancy Outcomes Following COVID-19 Vaccination: Preterm, Stillbirth and Miscarriage
O226 Pregnancy Outcomes Following COVID-19 Vaccination: Preterm, Stillbirth and Miscarriage
Speaker
Hee-Jin Kim(Ewha Womans University)
O227 Prenatal benzodiazepines or z-drugs use and risk of psychiatric disorders in children
O227 Prenatal benzodiazepines or z-drugs use and risk of psychiatric disorders in children
Speaker
Ahhyung Choi(School of Pharmacy, Sungkyunkwan University)
O228 Real-world drug exposure during pregnancy: Insights from the JDIIP database
O228 Real-world drug exposure during pregnancy: Insights from the JDIIP database
Speaker
Shinichi Matsuda(RAD-AR Council)
O229 Assessment of Maternal Dietary Pattern and Its effect on Early Gestational Period
O229 Assessment of Maternal Dietary Pattern and Its effect on Early Gestational Period
Speaker
Chippy Anna Joy(National Institute of Pharmaceutical Education and Research)
Cancer & Others
Details
Date
October Mon 14, 2024 11:30 - 13:00
Room
Faculty of Medicine Bldg. 1 (Venue M1-1F)(The University of Tokyo (Hongo Campus) Room 4)
Chairperson
O230 Twenty-year secular trend of thyrotoxicosis and thyrotoxic periodic paralysis in Hong Kong
O230 Twenty-year secular trend of thyrotoxicosis and thyrotoxic periodic paralysis in Hong Kong
Speaker
Gloria Hoi-Yee Li(The Hong Kong Polytechnic University)
O231 Effect of Biological Immunotherapy for Psoriasis on the Development of Psoriatic Arthritis
O231 Effect of Biological Immunotherapy for Psoriasis on the Development of Psoriatic Arthritis
Speaker
Yongtai Cho(Sungkyunkwan University)
O232 Role of Rare Disease Databases in Pharmacoepidemiological Studies in India: A Review
O232 Role of Rare Disease Databases in Pharmacoepidemiological Studies in India: A Review
Speaker
VENKATESH MADHUGIRI PRAKASH (JSS College of Pharmacy, Mysuru)
O233 Site-specific Cancer Incidence among Antipsychotic Users in Hong Kong: Descriptive Cohort Study
O233 Site-specific Cancer Incidence among Antipsychotic Users in Hong Kong: Descriptive Cohort Study
Speaker
Yuqi HU(the University of Hong Kong)
O234 Aspirin Use and Mortality Following a Cancer Diagnosis: A Clone-Censoring Weighting Method
O234 Aspirin Use and Mortality Following a Cancer Diagnosis: A Clone-Censoring Weighting Method
Speaker
Avery Shuei-He Yang(National Cheng-Kung University)
O235 Longevity of systematic reviews of PARP inhibitors in ovarian cancer
O235 Longevity of systematic reviews of PARP inhibitors in ovarian cancer
Speaker
Varri Naga Gowthami(National institute of pharmaceutical education and research)
Medication Access / Regulation
Details
Date
October Mon 14, 2024 11:30 - 13:00
Room
Faculty of Medicine Bldg. 1 (Venue M1-3F)(The University of Tokyo (Hongo Campus) Room 5)
Chairperson
O236 Access to Oral Childhood Cancer Medicines in High Income and LMIC Countries
O236 Access to Oral Childhood Cancer Medicines in High Income and LMIC Countries
Speaker
Dima M Qato(University of Southern California)
O237 Access to Monoclonal Antibody and Antibody-Drug Conjugates for Cancer Indication in Indonesia
O237 Access to Monoclonal Antibody and Antibody-Drug Conjugates for Cancer Indication in Indonesia
Speaker
Sudi Indra Jaya(Universitas Gadjah Mada)
O238 Descriptive analysis of outcomes in regulatory-required post-marketing database studies in Japan
O238 Descriptive analysis of outcomes in regulatory-required post-marketing database studies in Japan
Speaker
Hiroshi Yamazaki(Janssen Pharmaceutical K.K.)
O239 Prescriptions of the acid-suppressants after withdrawal of ranitidine in Korea
O239 Prescriptions of the acid-suppressants after withdrawal of ranitidine in Korea
Speaker
Jeong Pil Choi(Seoul National University)
O240 Decision-making Autonomy in Healthcare Utilization among Married Women and Associated Factors
O240 Decision-making Autonomy in Healthcare Utilization among Married Women and Associated Factors
Speaker
Sofa Dewi Alfian(Universitas Padjadjaran)
O241 Mapping five-year changes in childhood immunization in a South Indian community.
O241 Mapping five-year changes in childhood immunization in a South Indian community.
Speaker
Merrin Mathew (JSS College of Pharmacy, Mysuru)
Machine Learning/AI & Vacci.
Details
Date
October Mon 14, 2024 16:00 - 17:30
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
O242 Machine learning for high-risk multimorbid antipsychotic user identification and cardiovascular event prediction
O242 Machine learning for high-risk multimorbid antipsychotic user identification and cardiovascular event prediction
Speaker
Qi Sun(the University of Hong Kong)
O243 Artificial Intelligence Techniques for the Survival Prediction of Oropharyngeal Squamous Cell Carcinoma
O243 Artificial Intelligence Techniques for the Survival Prediction of Oropharyngeal Squamous Cell Carcinoma
Speaker
Krishna Undela(National Institute of Pharmaceutical Education and Research)
O244 Computational drug repurposing for gallbladder cancer integrated with pharmacovigilance approach
O244 Computational drug repurposing for gallbladder cancer integrated with pharmacovigilance approach
Speaker
vismitha varghese(NIPER Guwahati)
O245 AI in Pharmacovigilance: Asia Pacific's Scientific and Public Discourse
O245 AI in Pharmacovigilance: Asia Pacific's Scientific and Public Discourse
Speaker
Grace Wangge(Monash University, Indonesia)
O246 Risk of Guillain-Barre syndrome after Influenza Vaccination in Korean Adults
O246 Risk of Guillain-Barre syndrome after Influenza Vaccination in Korean Adults
Speaker
Haerin Cho(Ewha womans university)
O247 Trends and predictors of zoster vaccination coverage among U.S. cardiovascular disease population
O247 Trends and predictors of zoster vaccination coverage among U.S. cardiovascular disease population
Speaker
Ho Chieh Yu(Taipei Medical University)
Molecular & Covid - 19
Details
Date
October Mon 14, 2024 16:00 - 17:30
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Room 2)
Chairperson
O248 Association of vitamin D Status with various biomarkers in diabetic foot infection
O248 Association of vitamin D Status with various biomarkers in diabetic foot infection
Speaker
Ruby Benson(Manipal College of Pharmaceutical Sciences)
O249 Nationwide Cross Sectional Study for Local Polypharmacy by NDB data during COVID-19
O249 Nationwide Cross Sectional Study for Local Polypharmacy by NDB data during COVID-19
Speaker
Takehiro Ishida(Teikyo University School of Public Health)
O251 Metformin's impact on post-COVID-19 condition risk in overweight/obese individuals in the UK
O251 Metformin's impact on post-COVID-19 condition risk in overweight/obese individuals in the UK
Speaker
Ubonphan Chaichana(UCL School of Pharmacy)
O252 Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in COVID-19 Patients with Type-2 Diabetes
O252 Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in COVID-19 Patients with Type-2 Diabetes
Speaker
Zoey Cho Ting Wong(The University of Hong Kong)
O253 Irrational Consumption of Ivermectin During the COVID-19 Pandemic: Data From 67 Countries
O253 Irrational Consumption of Ivermectin During the COVID-19 Pandemic: Data From 67 Countries
Speaker
Daniel Hsiang-Te Tsai(National Cheng Kung University)
Medication Adherence
Details
Date
October Mon 14, 2024 16:00 - 17:30
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Room 3)
Chairperson
O254 Development of Novel Medication Adherence Scale for Chronic Diseases Patients In Indonesia
O254 Development of Novel Medication Adherence Scale for Chronic Diseases Patients In Indonesia
Speaker
Qisty Aulia Khoiry(Universitas Padjadjaran)
O255 Association between coordinated care and adherence to antihypertensive medicines among adults experiencing polypharmacy in Australia
O255 Association between coordinated care and adherence to antihypertensive medicines among adults experiencing polypharmacy in Australia
Speaker
Jialing Lin(University of New South Wales)
O256 Assessment Of Medication Adherence And The Impact Of Patient Education On Medication Adherence Among Polycystic Ovarian Syndrome Patients
O256 Assessment Of Medication Adherence And The Impact Of Patient Education On Medication Adherence Among Polycystic Ovarian Syndrome Patients
Speaker
SHILPA CLARA JOSEPH(JSS College of Pharmacy, Mysuru)
O257 Patterns of medication adherence to lipid-lowering therapy in primary care
O257 Patterns of medication adherence to lipid-lowering therapy in primary care
Speaker
Caroline Trin(Monash University)
O258 Impact of Same-Day ART on Care and Medication Discontinuation Among HIV/AIDS Patients
O258 Impact of Same-Day ART on Care and Medication Discontinuation Among HIV/AIDS Patients
Speaker
Hsiao Jou Yu(National Yang Ming Chiao Tung University)
O259 Development and pre-validation of the medication treatment satisfaction instrument for children and adolescents aged 8-18 years old
O259 Development and pre-validation of the medication treatment satisfaction instrument for children and adolescents aged 8-18 years old
Speaker
Mengting Yang(West China Second University Hospital, Sichuan University)
Psychiatric
Details
Date
October Mon 14, 2024 16:00 - 17:30
Room
Faculty of Medicine Bldg. 1 (Venue M1-1F)(The University of Tokyo (Hongo Campus) Room 4)
Chairperson
O260 The use of ADHD medication and the risk of suicide attempt (Rising Star Awardee)
O260 The use of ADHD medication and the risk of suicide attempt (Rising Star Awardee)
Speaker
Adrienne Chan(The University of Hong Kong)
O261 Evidence base for off-label use of psychotropic medications in adolescents with depression
O261 Evidence base for off-label use of psychotropic medications in adolescents with depression
Speaker
Menghuan Song(University of Macau, Institute of Chinese Medical Sciences)
O262 Suicidality and vortioxetine in adolescents and young adults: disproportionality analysis using FAERS
O262 Suicidality and vortioxetine in adolescents and young adults: disproportionality analysis using FAERS
Speaker
Thi Hong Nhung Trinh(University of Oslo)
O263 Self-harm and the use of leukotriene receptor antagonists and inhaled corticosteroids
O263 Self-harm and the use of leukotriene receptor antagonists and inhaled corticosteroids
Speaker
Boqing Chen(School of Pharmacy, University College London)
O264 Association of hydroxychloroquine and psychiatric disorders among patients with systemic lupus erythematosus
O264 Association of hydroxychloroquine and psychiatric disorders among patients with systemic lupus erythematosus
Speaker
Brian Li(National Cheng Kung University)
O265 Medication Treatment Patterns for Attention-Deficit/Hyperactivity Disorder in Chinese Children and Adolescents
O265 Medication Treatment Patterns for Attention-Deficit/Hyperactivity Disorder in Chinese Children and Adolescents
Speaker
Si Chen(China Pharmaceutical University)
Cancer - Breast & Prostate
Details
Date
October Mon 14, 2024 16:00 - 17:30
Room
Faculty of Medicine Bldg. 1 (Venue M1-3F)(The University of Tokyo (Hongo Campus) Room 5)
Chairperson
O266 Dihydropyrimidine dehydrogenase deficiency genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. Cost-effectiveness analysis.
O266 Dihydropyrimidine dehydrogenase deficiency genotyping-guided fluoropyrimidine-based adjuvant chemotherapy for breast cancer. Cost-effectiveness analysis.
Speaker
Dina Abushanab(Monash University)
O267 Risk of endometrial cancer by endocrine therapy for breast cancer in Japan
O267 Risk of endometrial cancer by endocrine therapy for breast cancer in Japan
Speaker
Chitose Kawamura(University of Tsukuba)
O268 Cardiotoxicity in postmenopausal breast cancer: a comparison of aromatase inhibitors and tamoxifen
O268 Cardiotoxicity in postmenopausal breast cancer: a comparison of aromatase inhibitors and tamoxifen
Speaker
Shu-Chen Hu(National Taiwan University)
O269 Cardiovascular Risks in Prostate Cancer Patients Using Adjunct Treatment
O269 Cardiovascular Risks in Prostate Cancer Patients Using Adjunct Treatment
Speaker
Tung Hiu Li(The University Of Hong Kong)
O270 Primary Prevention of Hormonal Treatment-related Cardiovascular Events in High-Risk Prostate Cancer Patients
O270 Primary Prevention of Hormonal Treatment-related Cardiovascular Events in High-Risk Prostate Cancer Patients
Speaker
Tung Hiu Li(The University Of Hong Kong)
O271 Incidence of type 2 diabetes mellitus in men initiated tadalafil
O271 Incidence of type 2 diabetes mellitus in men initiated tadalafil
Speaker
Atsushi Takayama(Kyoto University)
Poster 1
Poster in Venue E2: P100~P187+P701
Poster in Venue E2: P100~P187+P701
Details
Date
October Sun 13, 2024 08:00 - 18:00
Room
Faculty of Engineering Bldg. 2 (Venue E2)(The University of Tokyo (Hongo Campus) Poster 1)
Chairperson
P100 Adherence Trajectories to Aromatase Inhibitors in Postmenopausal Breast Cancer: A Five-Year Study
P100 Adherence Trajectories to Aromatase Inhibitors in Postmenopausal Breast Cancer: A Five-Year Study
Speaker
Wen Li Kuan(National Taiwan University)
P101 ART Adherence and its Associated Barrier Experienced by PLHIV in Mizoram, India.
P101 ART Adherence and its Associated Barrier Experienced by PLHIV in Mizoram, India.
Speaker
IRENE LALHRUAIMAWII(MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES)
P102 Clinical Pharmacist’s Intervention to Improve Medication Adherence in Patients Receiving Oral Oncolytics
P102 Clinical Pharmacist’s Intervention to Improve Medication Adherence in Patients Receiving Oral Oncolytics
Speaker
Krishna Undela(National Institute of Pharmaceutical Education and Research)
P103 Development and validation of medication adherence questionnaire for patients with chronic illnesses in Southern India
P103 Development and validation of medication adherence questionnaire for patients with chronic illnesses in Southern India
Speaker
Jeslin Theres Thomas(JSS College of Pharmacy, Mysuru)
P104 Impact of CPE program on medication adherence among community pharmacists
P104 Impact of CPE program on medication adherence among community pharmacists
Speaker
Jennifer James (JSS COLLEGE of PHARMACY)
P105 Knowledge, medication beliefs and adherence in diabetes patients:A structural equation modelling
P105 Knowledge, medication beliefs and adherence in diabetes patients:A structural equation modelling
Speaker
Indriastuti Cahyaningsih(Universitas Muhammadiyah Yogyakarta)
P106 Real-world persistence with second-line IL-17i and IL-23i treatment for psoriasis in Japan
P106 Real-world persistence with second-line IL-17i and IL-23i treatment for psoriasis in Japan
Speaker
Tong Li(Global Epidemiology, Janssen Research & Development, LLC)
P107 Statin Medication Adherence in Relation to Dyslipidemia Risk Categories
P107 Statin Medication Adherence in Relation to Dyslipidemia Risk Categories
Speaker
Kenji Momo(Showa University)
P108 Comparative evaluation of generative large language models in adverse drug reaction prediction
P108 Comparative evaluation of generative large language models in adverse drug reaction prediction
Speaker
Yen Ling Koon(Health Sciences Authority)
P109 ePhenotyping: machine learning approach for defining diabetic kidney disease as an outcome
P109 ePhenotyping: machine learning approach for defining diabetic kidney disease as an outcome
Speaker
Shinsuke Ohnuki(EPS Corporation)
P110 Investigating NAFLD Patient Phenotypes in Southern Taiwan Using Machine Learning-based Cluster Analysis
P110 Investigating NAFLD Patient Phenotypes in Southern Taiwan Using Machine Learning-based Cluster Analysis
Speaker
Chuan Wei Shen(School of Pharmacy, Kaohsiung Medical University)
P111 Machine learning predicting risk of infection among patients treated with b/ts DMARDs
P111 Machine learning predicting risk of infection among patients treated with b/ts DMARDs
Speaker
Kuan Peng(University of Hong Kong)
P112 Development of pulsatile drug delivery system of Bambuterol for treatment of Asthma
P112 Development of pulsatile drug delivery system of Bambuterol for treatment of Asthma
Speaker
SANJAY J(JSS College of Pharmacy)
P113 Reliever use and asthma control among U.S. adults with asthma, 2007-2020
P113 Reliever use and asthma control among U.S. adults with asthma, 2007-2020
Speaker
Chun Tse Hung(Taipei Medical University)
P114 Trends in Use of Asthma Inhalers with High Global Warming Potential
P114 Trends in Use of Asthma Inhalers with High Global Warming Potential
Speaker
Dima M Qato(University of Southern California)
P115 Belimumab utilization evaluation at a tertiary hospital in Taiwan
P115 Belimumab utilization evaluation at a tertiary hospital in Taiwan
Speaker
YEH-HAO LIAO(Linkou Chang Gung Memorial Hospital)
P116 Efficacy of telitacicept in the treatment of SLE: a network meta-analysis
P116 Efficacy of telitacicept in the treatment of SLE: a network meta-analysis
Speaker
Xintong He(IQVIA)
P117 Forecasting the incidence and prevalence of inflammatory bowel disease in three countries
P117 Forecasting the incidence and prevalence of inflammatory bowel disease in three countries
Speaker
Qiwen Fang(The University of Hong Kong)
P118 Interaction of Disease Modifying Anti Rhematoid Drugs in A Public District Hospital
P118 Interaction of Disease Modifying Anti Rhematoid Drugs in A Public District Hospital
Speaker
Mohammad Bakhriansyah(Universitas Lambung Mangkurat)
P119 Aspirin for Prophylaxis of VTE: Systematic Review and Meta-analysis of Non-Randomized Studies
P119 Aspirin for Prophylaxis of VTE: Systematic Review and Meta-analysis of Non-Randomized Studies
Speaker
Raghava Kalyan Maddukuri(Chebrolu Hanumaiah Institute of Pharmaceutical Sciences)
P120 Association between antihypertensive types and hospital stay and mortality in stroke patients
P120 Association between antihypertensive types and hospital stay and mortality in stroke patients
Speaker
Alfi Yasmina(Universitas Lambung Mangkurat)
P121 Blood pressure variability and risk of cardiovascular events in real-world clinical settings
P121 Blood pressure variability and risk of cardiovascular events in real-world clinical settings
Speaker
LU CHUNG-YEN(Da-Yeh University)
P122 Cognitive Impairment Among Patients with Cardiovascular Diseases: Comparisons of Sex, Elderly, Education
P122 Cognitive Impairment Among Patients with Cardiovascular Diseases: Comparisons of Sex, Elderly, Education
Speaker
Dujrudee Chinwong(Chiang Mai University)
P123 Combination therapy with sacubitril/valsartan and SGLT2 inhibitors for HFrEF with renal dysfunction
P123 Combination therapy with sacubitril/valsartan and SGLT2 inhibitors for HFrEF with renal dysfunction
Speaker
Tung-Chun Chien(National Taiwan University)
P125 Different potency of statin on major adverse cardiovascular events among Taiwanese patients
P125 Different potency of statin on major adverse cardiovascular events among Taiwanese patients
Speaker
Yen Hsun Chen(National Cheng Kung University, Tainan, Taiwan)
P126 Discrepancies between Prescribed and Defined Daily Doses of Four-Pillar Therapy in Congestive Heart Failure Patients
P126 Discrepancies between Prescribed and Defined Daily Doses of Four-Pillar Therapy in Congestive Heart Failure Patients
Speaker
NIKITA PAL(JSS College of Pharmacy, Mysuru)
P127 Epidemiology of Worsening Chronic Heart Failure: A Population-based Retrospective Cohort Study
P127 Epidemiology of Worsening Chronic Heart Failure: A Population-based Retrospective Cohort Study
Speaker
Xuan Yin(China Pharmaceutical University)
P128 Epidemiology, characteristics, and prognosis of heart failure with partial improved ejection fraction
P128 Epidemiology, characteristics, and prognosis of heart failure with partial improved ejection fraction
Speaker
Xuan Yin(China Pharmaceutical University)
P129 Evaluation of Clinical Characteristics and 90-day Outcomes amongst Heart Failure Patients: Insights from a Tertiary-care Hospital Settings
P129 Evaluation of Clinical Characteristics and 90-day Outcomes amongst Heart Failure Patients: Insights from a Tertiary-care Hospital Settings
Speaker
NIKITA PAL(JSS College of Pharmacy, Mysuru)
P130 Identification of Drug-related Problems Associated with Stroke Management: A Hospital- based Observational Study
P130 Identification of Drug-related Problems Associated with Stroke Management: A Hospital- based Observational Study
Speaker
Aarohi Vashi(JSS College of Pharmacy, Mysuru)
P131 Knowledge, Attitude & Practice of Patients Toward Cardiovascular Disorders Attending the Out-Patient Department of Cardiology
P131 Knowledge, Attitude & Practice of Patients Toward Cardiovascular Disorders Attending the Out-Patient Department of Cardiology
Speaker
NIKITA PAL(JSS College of Pharmacy, Mysuru)
P132 Long-term use of beta-blocker therapy after myocardial infarction
P132 Long-term use of beta-blocker therapy after myocardial infarction
Speaker
Caroline Trin(Monash University)
P133 Lower Limb Amputation Association with Sodium-Glucose co-Transporter-2 inhibitors: Systematic review and Meta-Analysis
P133 Lower Limb Amputation Association with Sodium-Glucose co-Transporter-2 inhibitors: Systematic review and Meta-Analysis
Speaker
Solaiman Alhawas(SFDA)
P134 Outcomes of PCSK9 Inhibitors users with ASCVD: a cohort study in China
P134 Outcomes of PCSK9 Inhibitors users with ASCVD: a cohort study in China
Speaker
Tiantian Ma(Laboratory of Data Discovery for Health)
P135 Prescription Patterns of Lipid-lowering Therapies in Patients with Atherosclerotic Cardiovascular Disease (ASCVD)
P135 Prescription Patterns of Lipid-lowering Therapies in Patients with Atherosclerotic Cardiovascular Disease (ASCVD)
Speaker
NIKITA PAL(JSS College of Pharmacy, Mysuru)
P136 Prescription patterns of oral anticoagulants in older adults with atrial fibrillation
P136 Prescription patterns of oral anticoagulants in older adults with atrial fibrillation
Speaker
Shota Hamada(Institute for Health Economics and Policy)
P137 Real-World Characteristics, Treatment Patterns, and Outcomes in Patients with ASCVD in China
P137 Real-World Characteristics, Treatment Patterns, and Outcomes in Patients with ASCVD in China
Speaker
Jiamei Liu(China Pharmaceutical University)
P139 Risk of cancer comparing warfarin and direct oral anticoagulants
P139 Risk of cancer comparing warfarin and direct oral anticoagulants
Speaker
Zixuan Wang(London School of Hygiene and Tropical Medicine)
P140 Risk of Stroke Associated with NSAID among Osteoarthritis Patients with Atrial Fibrillation
P140 Risk of Stroke Associated with NSAID among Osteoarthritis Patients with Atrial Fibrillation
Speaker
Zhen-Fang Lin(National Taiwan University)
P141 Sodium-glucose cotransporter 2 inhibitors and cardiovascular events across body mass index
P141 Sodium-glucose cotransporter 2 inhibitors and cardiovascular events across body mass index
Speaker
Hwa Yeon Ko(Sungkyunkwan University)
P142 Statins and intracerebral hemorrhage risk: a target trial emulation study in China
P142 Statins and intracerebral hemorrhage risk: a target trial emulation study in China
Speaker
Yang Xu(Peking University Health Services Centre)
P143 Systematic review and meta-analysis of DOACs versus LMWH in Cancer-Associated venous Thrombosis
P143 Systematic review and meta-analysis of DOACs versus LMWH in Cancer-Associated venous Thrombosis
Speaker
Wei KANG(The University of Hong Kong)
P144 Trend of treatment patterns and lipid control for primary prevention of ASCVD
P144 Trend of treatment patterns and lipid control for primary prevention of ASCVD
Speaker
Qiuyan Yu(University of Hong Kong)
P145 Trends in Obstructive Sleep Apnea incidence in Taiwan from 2004 to 2020
P145 Trends in Obstructive Sleep Apnea incidence in Taiwan from 2004 to 2020
Speaker
Zhen Han Oh(Shuangho hospital ministry of health and welfare)
P146 Evaluation of clinical and economic implications of adverse drug reactions in a tertiary care teaching hospital.
P146 Evaluation of clinical and economic implications of adverse drug reactions in a tertiary care teaching hospital.
Speaker
D S Sindoora(JSS College of Pharmacy, Mysuru)
P147 Examining Quality of Life in Individuals Experiencing Adverse Drug Reactions: The Application of the WHOQOL-BREF Scale for Evaluation
P147 Examining Quality of Life in Individuals Experiencing Adverse Drug Reactions: The Application of the WHOQOL-BREF Scale for Evaluation
Speaker
Marwa Muhammed(JSS College of Pharmacy)
P148 Cost-effectiveness analysis of the first-line treatment with nivolumab plus ipilimumab in mesothelioma
P148 Cost-effectiveness analysis of the first-line treatment with nivolumab plus ipilimumab in mesothelioma
Speaker
zhaoyan chen(West China Hospital of Sichuan University)
P149 Economic evaluation of medical expenses in home medical care (Zaitaku) using NDB
P149 Economic evaluation of medical expenses in home medical care (Zaitaku) using NDB
Speaker
Ishii Kazuo(Suwa University of Science)
P150 Health economic evaluation of self-injection of biologics in patients with rheumatoid arthritis.
P150 Health economic evaluation of self-injection of biologics in patients with rheumatoid arthritis.
Speaker
Kazuhiko Takahata(Meiji Pharmaceutical University)
P151 Quality of Life in Post Stroke Patients: Impact of Clinical factors.
P151 Quality of Life in Post Stroke Patients: Impact of Clinical factors.
Speaker
Raghava Kalyan Maddukuri(Chebrolu Hanumaiah Institute of Pharmaceutical Sciences)
P152 Research on the evidence development of benefit-risk in TCM formula granules
P152 Research on the evidence development of benefit-risk in TCM formula granules
Speaker
Yunfeng Lai(Guangzhou University of Chinese Medicine)
P153 Association of COVID-19 Policy Stringency on Patient Satisfaction in Chinese Community Pharmacy
P153 Association of COVID-19 Policy Stringency on Patient Satisfaction in Chinese Community Pharmacy
Speaker
Ruijian Huang(China Pharmaceutical University)
P154 Effects of COVID-19 on Infectious Events in Patients with CLL in China
P154 Effects of COVID-19 on Infectious Events in Patients with CLL in China
Speaker
Yin Liu(China Pharmaceutical University)
P155 Health equity of COVID-19 monoclonal antibodies at a US medical center
P155 Health equity of COVID-19 monoclonal antibodies at a US medical center
Speaker
Anna Kiyomi(Tokyo University of Pharmacy and Life Sciences)
P156 Healthcare utilization and disease status of herpes zoster during COVID-19 pandemic
P156 Healthcare utilization and disease status of herpes zoster during COVID-19 pandemic
Speaker
Jin-Yi Lin(Department of Pharmacy, Taipei City Hospital Zhongxing Branch)
P157 How the Characteristics and Pattern of SARS CoV-2 Affected Their Virulence
P157 How the Characteristics and Pattern of SARS CoV-2 Affected Their Virulence
Speaker
Rezvi SM(Universitas Andalas)
P158 Impact of COVID-19 pandemic on adherence to antidepressants in Saudi Arabia
P158 Impact of COVID-19 pandemic on adherence to antidepressants in Saudi Arabia
Speaker
Khalid Orayj(King Khalid University)
P159 Molnupiravir for non-hospitalized adults with mild/moderately severe coronavirus disease 2019 (COVID-19)
P159 Molnupiravir for non-hospitalized adults with mild/moderately severe coronavirus disease 2019 (COVID-19)
Speaker
George Okoli(The University of Hong Kong)
P160 Nirmatrelvir-ritonavir regimen for non-hospitalized adults with mild/moderately severe coronavirus disease 2019 (COVID-19)
P160 Nirmatrelvir-ritonavir regimen for non-hospitalized adults with mild/moderately severe coronavirus disease 2019 (COVID-19)
Speaker
George Okoli(The University of Hong Kong)
P161 Post-COVID19 Perception, Knowledge, and Phobia towards Corticosteroids among the General Public
P161 Post-COVID19 Perception, Knowledge, and Phobia towards Corticosteroids among the General Public
Speaker
Mohammed Salim Karattuthodi(Manipal College of Pharmaceutical Sciences)
P162 Risk of mortality of COVID-19 & influenza co-infection: A clone-censor-weight study
P162 Risk of mortality of COVID-19 & influenza co-infection: A clone-censor-weight study
Speaker
Chi Him Lau(The University of Hong Kong)
P701 Effectiveness of Nirmatrelvir-Ritonavir on Patients with COVID-19: A Nationwide Study in Taiwan
P701 Effectiveness of Nirmatrelvir-Ritonavir on Patients with COVID-19: A Nationwide Study in Taiwan
Speaker
Raymond Kuo(National Taiwan University)
P163 Risk of narcolepsy after COVID-19 vaccination in Korea: self-controlled case series study
P163 Risk of narcolepsy after COVID-19 vaccination in Korea: self-controlled case series study
Speaker
Suvin Park(Ewha Womans University)
P164 Self-medication among elderly during COVID-19 in Macao: a cross-sectional study
P164 Self-medication among elderly during COVID-19 in Macao: a cross-sectional study
Speaker
Yu Zheng(University Of Macau)
P165 The health condition after COVID-19 infection stratified by initial disease-severity
P165 The health condition after COVID-19 infection stratified by initial disease-severity
Speaker
Ran Zhang(The University of Hong Kong)
P166 The Impact of COVID-19 restrictions on Emergency Bellwether Procedures in Asia
P166 The Impact of COVID-19 restrictions on Emergency Bellwether Procedures in Asia
Speaker
Sze Ling Chan(SingHealth)
P167 The Psychological Impact of the COVID-19 Pandemic on the General Population in India: Insights from a Nationwide Survey
P167 The Psychological Impact of the COVID-19 Pandemic on the General Population in India: Insights from a Nationwide Survey
Speaker
AMAL ANAND(Rutgers University)
P168 Vaccination is protective against post-Covid-19 multimorbidity incidence: a territory-wide retrospective cohort study
P168 Vaccination is protective against post-Covid-19 multimorbidity incidence: a territory-wide retrospective cohort study
Speaker
Boyan Liu(The University of Hong Kong)
P169 Investigation of Severe Hypoglycemia Risk among Lyumjev® Treated Diabetic Patients in Japan
P169 Investigation of Severe Hypoglycemia Risk among Lyumjev® Treated Diabetic Patients in Japan
Speaker
Machiko Minatoya(Eli Lilly Japan)
P170 Prevalence and predictors of adverse events with DPP-4 inhibitors: A cross-sectional study
P170 Prevalence and predictors of adverse events with DPP-4 inhibitors: A cross-sectional study
Speaker
Swetha R Reghunath(Manipal College of Pharmaceutical Sciences)
P171 Adherence to routine medical examinations among patients with type 2 diabetes mellitus
P171 Adherence to routine medical examinations among patients with type 2 diabetes mellitus
Speaker
Yu-Tung Huang(National Taiwan University)
P172 Anemia and SGLT2 Inhibitors in Patients with Diabetes across Different CKD Stages
P172 Anemia and SGLT2 Inhibitors in Patients with Diabetes across Different CKD Stages
Speaker
Jia Chian Hu(National Cheng Kung University, Taiwan)
P173 Assessment of Treatment Satisfaction, quality of life in Type 2 DM Patients
P173 Assessment of Treatment Satisfaction, quality of life in Type 2 DM Patients
Speaker
SAI PAWAN ADEPU(Vikas College of Pharmaceutical Sciences)
P174 Associated Factors of Cardiovascular Events in Diabetes Outpatients at Teaching Hospitals
P174 Associated Factors of Cardiovascular Events in Diabetes Outpatients at Teaching Hospitals
Speaker
Eka Kartika Untari(Gadjah Mada University)
P175 Association of metabolic comorbidities with chronic hepatitis B progression among Chinese patients
P175 Association of metabolic comorbidities with chronic hepatitis B progression among Chinese patients
Speaker
Meng Shu(Global Epidemiology, Janssen Research & Development, LLC)
P181 Comparison of Biguanides and DPP-4 Inhibitors on Cardio-Cerebrovascular Outcomes, Complications, and Costs
P181 Comparison of Biguanides and DPP-4 Inhibitors on Cardio-Cerebrovascular Outcomes, Complications, and Costs
Speaker
Eiji Nakatani(Graduate School of Medical Science Nagoya City University)
P176 Association of multimorbidity intervals with mortality among people with diabetes
P176 Association of multimorbidity intervals with mortality among people with diabetes
Speaker
Wenlong Liu(The University of Hong Kong)
P182 FINDRISC for detecting metabolic syndrome: Findings from an Indonesian national health survey
P182 FINDRISC for detecting metabolic syndrome: Findings from an Indonesian national health survey
Speaker
Rifqi Rokhman(Universitas Gadjah Mada)
P177 Benzodiazepines use in patients with obstructive sleep apnea and diabetes mellitus
P177 Benzodiazepines use in patients with obstructive sleep apnea and diabetes mellitus
Speaker
Liang-Chen Hsia(Taipei Medical University-Shuang Ho Hospital)
P183 Geographic variation in SGLT2i and GLP-1RA use for type 2 diabetes
P183 Geographic variation in SGLT2i and GLP-1RA use for type 2 diabetes
Speaker
Michael Falster(UNSW)
P178 Bridging the link between diabetes and chronotype: A first study in India
P178 Bridging the link between diabetes and chronotype: A first study in India
Speaker
A S Kamakshi Shriya(JSS College of Pharmacy, Mysuru)
P184 Risk analysis of ezetimibe and drug-induced liver injury in Taiwan
P184 Risk analysis of ezetimibe and drug-induced liver injury in Taiwan
Speaker
CHIH-HAN LIN(Taipei City Hospital Zhongxing Branch)
P179 Cardiovascular Outcomes in Patients with Type 2 Diabetes and Obstructive Sleep Apnea
P179 Cardiovascular Outcomes in Patients with Type 2 Diabetes and Obstructive Sleep Apnea
Speaker
Ting-Hsuan Lee(Taipei Medical University - Shuang Ho Hospital)
P185 Safety of SGLT2 inhibitors in type 1 diabetes: real-world experience in Japan
P185 Safety of SGLT2 inhibitors in type 1 diabetes: real-world experience in Japan
Speaker
Masato Takeuchi(Shizuoka Graduate University of Public Health)
P180 Cardiovascular risk of colchicine in patients with type 2 diabetes and gout
P180 Cardiovascular risk of colchicine in patients with type 2 diabetes and gout
Speaker
Minjeong Jeon(Sungkyunkwan University)
P186 Sodium-glucose cotransporter 2 inhibitors and suicide in patients with diabetes and depression
P186 Sodium-glucose cotransporter 2 inhibitors and suicide in patients with diabetes and depression
Speaker
Daniel Hsiang-Te Tsai(National Cheng Kung University)
P187 The association of SGLT2i versus DPP4i with incident anemia in Hong Kong.
P187 The association of SGLT2i versus DPP4i with incident anemia in Hong Kong.
Speaker
Chun Ming Philip Au(University of Hong Kong)
Poster 1
Poster in Venue E2: P300~P392
Poster in Venue E2: P300~P392
Details
Date
October Mon 14, 2024 08:00 - 18:00
Room
Faculty of Engineering Bldg. 2 (Venue E2)(The University of Tokyo (Hongo Campus) Poster 1)
Chairperson
P300 A study to assess drug related problems associated with anti-tubercular medications.
P300 A study to assess drug related problems associated with anti-tubercular medications.
Speaker
Shilpa Palaksha(JSS College of Pharmacy, JSS AHER, Mysuru)
P301 Adverse drug reaction in drug-resistant tuberculosis patients: a retrospective study
P301 Adverse drug reaction in drug-resistant tuberculosis patients: a retrospective study
Speaker
Galistiani Githa Fungie(Universitas Muhammadiyah Purwokerto)
P302 Antimicrobial treatment for inpatient bacterial bloodstream infection in Hong Kong (2012-2021)
P302 Antimicrobial treatment for inpatient bacterial bloodstream infection in Hong Kong (2012-2021)
Speaker
Guanhao Zheng(The University of Hong Kong)
P303 Assessing Metronidazole and Tinidazole for Anaerobic Infections: A Case-Control Study
P303 Assessing Metronidazole and Tinidazole for Anaerobic Infections: A Case-Control Study
Speaker
Vaishnavi Pawar(JSS College of Pharmacy, Mysuru Karnataka)
P304 Assessment of antimicrobial dosing appropriateness in chronic kidney disease patients
P304 Assessment of antimicrobial dosing appropriateness in chronic kidney disease patients
Speaker
Gayatri R Panicker(Manipal College of Pharmaceutical Sciences)
P305 Changing trends in influenza mortality among regions from 2001 to 2022
P305 Changing trends in influenza mortality among regions from 2001 to 2022
Speaker
SAKO NANAMI(Okayama University)
P306 Clinical and economic evaluation of Xuebijing injection for sepsis treatment in China
P306 Clinical and economic evaluation of Xuebijing injection for sepsis treatment in China
Speaker
Yunfeng Lai(Guangzhou University of Chinese Medicine)
P307 Comparative Effect of Four Antimalarial Treatments on Haematocrit in Children Southwest, Nigeria
P307 Comparative Effect of Four Antimalarial Treatments on Haematocrit in Children Southwest, Nigeria
Speaker
Zacchaeus Olofin(University of Ibadan)
P308 Comparing Effectiveness and Safety of Conventional versus Super-Bioavailable Itraconazole in Dermatophytosis
P308 Comparing Effectiveness and Safety of Conventional versus Super-Bioavailable Itraconazole in Dermatophytosis
Speaker
Apeksha Merja(Enliven Skin Care)
P309 Consumption and expenditure on fidaxomicin and oral vancomycin for Clostridioides difficile infection in 43 countries and regions
P309 Consumption and expenditure on fidaxomicin and oral vancomycin for Clostridioides difficile infection in 43 countries and regions
Speaker
Yin Zhang(The University of Hong Kong)
P310 DRUG INTERACTIONS IN PEOPLE LIVING WITH HIV WITH COMORBIDITIES VERSUS WITHOUT COMORBIDITIES
P310 DRUG INTERACTIONS IN PEOPLE LIVING WITH HIV WITH COMORBIDITIES VERSUS WITHOUT COMORBIDITIES
Speaker
Rajesh Radhakrishnan(Manipal College of Pharmaceutical sciences)
P312 Epidemiology of serious side effects from macrolide and risk management in Thailand
P312 Epidemiology of serious side effects from macrolide and risk management in Thailand
Speaker
Pakawadee Sriphiromya(Ministry of Public Health)
P313 Evaluation of role-play to improve community health workers knowledge on antimicrobial resistance.
P313 Evaluation of role-play to improve community health workers knowledge on antimicrobial resistance.
Speaker
Rosy Raju(JSS College of Pharmacy)
P314 Global influenza mortality trends: a joinpoint regression analysis
P314 Global influenza mortality trends: a joinpoint regression analysis
Speaker
Maki Yamamoto(Okayama University)
P315 Impact of direct-acting antiviral treatment on total cholesterol metabolism in hepatitis C
P315 Impact of direct-acting antiviral treatment on total cholesterol metabolism in hepatitis C
Speaker
Hsuan-Yu Hung(Kaohsiung Medical University)
P316 Knowledge, attitude and practice towards tuberculosis among students at a Saudi Arabia
P316 Knowledge, attitude and practice towards tuberculosis among students at a Saudi Arabia
Speaker
Dalia Almaghaslah(King Khalid University)
P317 Liver Enzymes During and After Artemether-Lumefantrine Therapy with Uncomplicated Plasmodium Falciparum Infection
P317 Liver Enzymes During and After Artemether-Lumefantrine Therapy with Uncomplicated Plasmodium Falciparum Infection
Speaker
Zacchaeus Olofin(University of Ibadan)
P318 Patterns of Antibiotic-Resistance and Multi-Drug Resistance in Clinical-Specimens: A Four-Year Retrospective Analysis
P318 Patterns of Antibiotic-Resistance and Multi-Drug Resistance in Clinical-Specimens: A Four-Year Retrospective Analysis
Speaker
ROVIN MATHEW THEEMPALANGAD(Centre for Clinical Research Excellence)
P319 Perception of antibiotic deprescribing among physicians in a tertiary healthcare facility
P319 Perception of antibiotic deprescribing among physicians in a tertiary healthcare facility
Speaker
Sonal Sekhar Miraj(Manipal College of Pharmaceutical Sciences)
P320 Perspectives of community pharmacy staff towards antimicrobial resistance: Findings from qualitative study
P320 Perspectives of community pharmacy staff towards antimicrobial resistance: Findings from qualitative study
Speaker
Rosy Raju(JSS College of Pharmacy)
P321 Post-marketing study to assess serotype-specific effectiveness of Rotavirus Vaccine (ROTATEQ®) in China
P321 Post-marketing study to assess serotype-specific effectiveness of Rotavirus Vaccine (ROTATEQ®) in China
Speaker
Jiahuang Lin(MSD R&D China)
P322 Quality appraisal of antibiotic use through defined daily dose in a south Indian hospital- A point prevalence study
P322 Quality appraisal of antibiotic use through defined daily dose in a south Indian hospital- A point prevalence study
Speaker
LINU MOHAN P(AL SHIFA COLLEGE OF PHARMACY)
P324 Reviewing and Improving Legislations to Tackle Antimicrobial Resistance
P324 Reviewing and Improving Legislations to Tackle Antimicrobial Resistance
Speaker
Sarah Altamimi(Saudi Food and Drug Authority)
P325 The Profile of Glucocorticoid-Induced Leucine Zipper Protein in Sepsis Patients with Comorbidity
P325 The Profile of Glucocorticoid-Induced Leucine Zipper Protein in Sepsis Patients with Comorbidity
Speaker
Mutia Lailani(Universitas Andalas)
P326 Trends in Seasonal Influenza Mortality From 2001 to 2022 in Fourteen Countries
P326 Trends in Seasonal Influenza Mortality From 2001 to 2022 in Fourteen Countries
Speaker
Mariko Fujii(Okayama University)
P327 Comparison of serum procalcitonin and C-reactive protein levels for diagnosis of AKI
P327 Comparison of serum procalcitonin and C-reactive protein levels for diagnosis of AKI
Speaker
Vijayanarayana Kunhikatta(Manipal College of Pharmaceutical Sciences)
P328 Economic Burden of Anemic Chronic Kidney Disease in China
P328 Economic Burden of Anemic Chronic Kidney Disease in China
Speaker
Yuqing Bao(China Pharmaceutical University)
P329 Longitudinal hemoglobin trajectories-associated major kidney outcomes in non-dialysis-dependent and dialysis-dependent CKD patients
P329 Longitudinal hemoglobin trajectories-associated major kidney outcomes in non-dialysis-dependent and dialysis-dependent CKD patients
Speaker
Zi-Yang Peng(National Cheng Kung University)
P330 Patient Journey of Diabetic Kidney Disease using an EMR database in Japan
P330 Patient Journey of Diabetic Kidney Disease using an EMR database in Japan
Speaker
Mio Kubo(EPS Corporation, Real World Evidence Headquarters)
P331 Prevalence and Treatment Patterns of Nocturnal Polyuria in Taiwan: Findings from the National Health Insurance Research Database
P331 Prevalence and Treatment Patterns of Nocturnal Polyuria in Taiwan: Findings from the National Health Insurance Research Database
Speaker
Yu-Tzu Tseng(Department of Pharmacy, National Taiwan University)
P332 Real-world evaluation of sevelamer in chronic kidney disease: a retrospective cohort study
P332 Real-world evaluation of sevelamer in chronic kidney disease: a retrospective cohort study
Speaker
Winnie Foo(Agency for Care Effectiveness, Ministry of Health)
P333 Travel and accessibility challenges in dialysis patients: A survey
P333 Travel and accessibility challenges in dialysis patients: A survey
Speaker
Prasanna Kumar(Manipal College of Pharmaceutical Sciences)
P334 (CAR) T cell Immunotherapies and Potential association of Secondary T-Cell Malignancies
P334 (CAR) T cell Immunotherapies and Potential association of Secondary T-Cell Malignancies
Speaker
Maha Alghamdi(Saudi food and drug Authority)
P335 Adverse events after receiving denosumab among solid tumor cancer patients in Taiwan
P335 Adverse events after receiving denosumab among solid tumor cancer patients in Taiwan
Speaker
Wei-Ju Chen(Amgen Taiwan Limited.)
P336 Cancer Drug Use of Childhood Cancer Patients in China: A Cross-sectional Analysis
P336 Cancer Drug Use of Childhood Cancer Patients in China: A Cross-sectional Analysis
Speaker
Yichen Zhang(Peking University)
P337 Cardiac Injury in Non-Small Cell Lung Cancer Patients on Immune Checkpoint Inhibitors
P337 Cardiac Injury in Non-Small Cell Lung Cancer Patients on Immune Checkpoint Inhibitors
Speaker
Xuan Yin(China Pharmaceutical University)
P338 Characteristics of Diffuse Large B-cell Lymphoma Patients receiving R-CHOP Therapy with/without G-CSF
P338 Characteristics of Diffuse Large B-cell Lymphoma Patients receiving R-CHOP Therapy with/without G-CSF
Speaker
Nagao Osamu(RAD-AR Council)
P339 Characteristics, treatment, clinical outcomes in Chinese CLL following discontinuation of BTKi therapy
P339 Characteristics, treatment, clinical outcomes in Chinese CLL following discontinuation of BTKi therapy
Speaker
Jiahuang Lin(MSD R&D China)
P340 Comparative Evaluation of PEG-rhG-CSF vs rhG-CSF for Febrile Neutropenia in Lymphoma
P340 Comparative Evaluation of PEG-rhG-CSF vs rhG-CSF for Febrile Neutropenia in Lymphoma
Speaker
qu ying(The Third Affiliated Hospital of Soochow University)
P341 COMPARISON OF ADVERSE DRUG REACTIONS IN BONE MARROW TRANSPLANT AND HEMAT-ONCO SETTING
P341 COMPARISON OF ADVERSE DRUG REACTIONS IN BONE MARROW TRANSPLANT AND HEMAT-ONCO SETTING
Speaker
LITTY K(MS RAMAIAH UNIVERSITY OF APPLIED SCIENCES)
P342 Differences for CLL Patients Between China and US: A Large-Scale Comparative Study
P342 Differences for CLL Patients Between China and US: A Large-Scale Comparative Study
Speaker
Yin Liu(China Pharmaceutical University)
P343 Disproportionality analysis on immune checkpoint inhibitors using a spontaneous adverse event reporting
P343 Disproportionality analysis on immune checkpoint inhibitors using a spontaneous adverse event reporting
Speaker
Ju Won Lee(Chung-Ang University)
P344 Early-Onset Gastric and Colorectal Cancer in Japan and the US
P344 Early-Onset Gastric and Colorectal Cancer in Japan and the US
Speaker
Elsie Horne(Flatiron Health)
P345 Exploration of theragnostic target along the central dogma of anaplastic thyroid cancer
P345 Exploration of theragnostic target along the central dogma of anaplastic thyroid cancer
Speaker
USHNAA KURI(Ramaiah University of Applied Sciences)
P346 Investigating the preventive colorectal cancer screening among US adults by diabetes status
P346 Investigating the preventive colorectal cancer screening among US adults by diabetes status
Speaker
Yu Tzu Chen(Taipei Medical University)
P347 P+C+OMCT vs. TPF regimen as neoadjuvant chemotherapy in head & neck cancer
P347 P+C+OMCT vs. TPF regimen as neoadjuvant chemotherapy in head & neck cancer
Speaker
Shruti Soni (L. M. College of Pharmacy)
P348 Predict prostate cancer mortality: an application of real-world data-driven, time-inhomogeneous Markov model
P348 Predict prostate cancer mortality: an application of real-world data-driven, time-inhomogeneous Markov model
Speaker
Jiaqi Wang(The University of Hong Kong)
P349 Prevalence and trajectories of multiple medicine use in people with colorectal cancer
P349 Prevalence and trajectories of multiple medicine use in people with colorectal cancer
Speaker
Benjamin Daniels(UNSW Sydney)
P350 Real-world Treatment Patterns of Trastuzumab Deruxtecan (T-DXd) in Chinese Breast Cancer Patients
P350 Real-world Treatment Patterns of Trastuzumab Deruxtecan (T-DXd) in Chinese Breast Cancer Patients
Speaker
FAN YANG(China Pharmaceutical University)
P351 Recent Review of Population-based Cancer Registries in the US, Europe, and Korea
P351 Recent Review of Population-based Cancer Registries in the US, Europe, and Korea
Speaker
Minji Kim(Ewha W.University)
P352 Relationship between Dose Intensity and Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors
P352 Relationship between Dose Intensity and Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors
Speaker
MING-YI HUANG(Linkou Chang Gung Memorial Hospital)
P353 Safety evaluation of rituximab biosimilar products using real-world data in Japan
P353 Safety evaluation of rituximab biosimilar products using real-world data in Japan
Speaker
Kimie Sai(National Institute of Health Sciences)
P354 Systemic exposure of VEGF/VEGFR inhibitors: artery dissection risk assessment using claims data
P354 Systemic exposure of VEGF/VEGFR inhibitors: artery dissection risk assessment using claims data
Speaker
Takashi Waki(Pharmaceuticals and Medical Devices Agency)
P355 Tamoxifen and risk of uterine diseases in young women with breast cancer
P355 Tamoxifen and risk of uterine diseases in young women with breast cancer
Speaker
Pei-Chun Chen(National Health Research Institutes)
P356 Design and synthesize the potent and less toxic HoLu-7 as anticancer agent
P356 Design and synthesize the potent and less toxic HoLu-7 as anticancer agent
Speaker
Hui Hsia Hsieh(Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation)
P357 Evaluation of Drug Utilization of Trastuzumab Deruxtecan in a Regional Hospital
P357 Evaluation of Drug Utilization of Trastuzumab Deruxtecan in a Regional Hospital
Speaker
Tzu Cheng Wang(Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation)
P358 A systematic review of healthcare professionals’ capacity building in regenerative medicine
P358 A systematic review of healthcare professionals’ capacity building in regenerative medicine
Speaker
Junnan Shi(University of Macau)
P359 Assessment of Knowledge, Attitude, Practice Towards Appropriate Medication Usein High School
P359 Assessment of Knowledge, Attitude, Practice Towards Appropriate Medication Usein High School
Speaker
MANJULA SANTHEPETE(JSS COLLEGE OF PHARMACY,MYSURU)
P360 A scoping review on the research landscape of Fentanyl in pediatric oncology.
P360 A scoping review on the research landscape of Fentanyl in pediatric oncology.
Speaker
SHWETHA SOMAKUMAR(Manipal College of Pharmaceutical Sciences)
P361 Comparative Study of Morphine versus Tapentadol in Cancer Pain Management
P361 Comparative Study of Morphine versus Tapentadol in Cancer Pain Management
Speaker
Rajesh V(Manipal College of Pharmaceutical Sciences)
P362 The rate of naloxone use in emergency departments in the United States
P362 The rate of naloxone use in emergency departments in the United States
Speaker
Minji Sohn(Ferris State University)
P363 Utilization patterns of analgesics in Indian cancer patients: systematic review and meta-analysis"
P363 Utilization patterns of analgesics in Indian cancer patients: systematic review and meta-analysis"
Speaker
Vani Mahathi Bulusu(All India Institute of Medical Sciences)
P364 Adverse drug reactions of Vitamin D: trends in Jiangsu and signal detection
P364 Adverse drug reactions of Vitamin D: trends in Jiangsu and signal detection
Speaker
Hui Xue(Southeast University)
P365 Bisphosphonates’ Impact on Pain and Quality of Life in Osteoporosis Patients
P365 Bisphosphonates’ Impact on Pain and Quality of Life in Osteoporosis Patients
Speaker
Pandji Winata Nurikhwan(Universitas Lambung Mangkurat)
P366 Utilization of romosozumab in osteoporosis patients: A real-world evidence from Taiwan
P366 Utilization of romosozumab in osteoporosis patients: A real-world evidence from Taiwan
Speaker
CHIA CHEN WU(LinKou Chang Gung Memorial Hospital)
P367 Renal Outcomes and Mortality in DME: Aflibercept vs. Ranibizumab
P367 Renal Outcomes and Mortality in DME: Aflibercept vs. Ranibizumab
Speaker
Wan-Ju Annabelle LEE(Chi Mei Medical Center)
P368 CFTR modulators for patients with cystic fibrosis: A Bayesian Network Meta-analysis
P368 CFTR modulators for patients with cystic fibrosis: A Bayesian Network Meta-analysis
Speaker
Mohammed Safeer(National Institute of Pharmaceutical Education and Research)
P369 Comparative Assessment of Pharmacoepidemiological studies of Rare Diseases in Japan and India
P369 Comparative Assessment of Pharmacoepidemiological studies of Rare Diseases in Japan and India
Speaker
Sangita Mishra(JSS College of Pharmacy, Mysuru)
P370 Efficacy and safety of stem-cell therapy in patients with muscular dystrophy
P370 Efficacy and safety of stem-cell therapy in patients with muscular dystrophy
Speaker
Nagita Devi(Chandigarh Group of Pharmacy, Landran, Punjab, India)
P371 Evaluation of treatment efficacy, risk factors in paraquat poisoning: a decade-long study
P371 Evaluation of treatment efficacy, risk factors in paraquat poisoning: a decade-long study
Speaker
Harsimran Kaur(Manipal College of Pharmaceutical Sciences)
P372 Impostor syndrome prevalence and factors among northern thai university students
P372 Impostor syndrome prevalence and factors among northern thai university students
Speaker
Siraprapa Kaewmart(Faculty of Pharmacy, Chiang Mai University)
P373 Indian traditional preparation of Liquorice in the post-operative pain management of haemorrhoids
P373 Indian traditional preparation of Liquorice in the post-operative pain management of haemorrhoids
Speaker
MRUTHUNJAYA KENGANORA(JSS COLLEGE OF PHARMACY, JSS ACADEMY OF HIGHER EDUCATION)
P374 Isolation and quantification of miRNAs from the human saliva
P374 Isolation and quantification of miRNAs from the human saliva
Speaker
Manthan Merja (Enliven Cancer Care)
P375 Post-marketing safety of ustekinumab for psoriasis based on 14-year follow-up in Danish national patient data
P375 Post-marketing safety of ustekinumab for psoriasis based on 14-year follow-up in Danish national patient data
Speaker
Sejun Kim(Danish National University Hospital "Rigshospitalet")
P376 Assessing the association between the combination use of diuretics and the risk of PDA-ligation among PDA infants
P376 Assessing the association between the combination use of diuretics and the risk of PDA-ligation among PDA infants
Speaker
Yung-Hsin Huang(National Cheng Kung University Hospital)
P377 Prolonged off-label antipsychotic therapy and cardiometabolic outcomes in children: a systematic review
P377 Prolonged off-label antipsychotic therapy and cardiometabolic outcomes in children: a systematic review
Speaker
Ramya Padmavathy Radha Krishnan(University of Sydney)
P378 Evaluating the Prognostic Value of the Status Epilepticus Severity Score in Children
P378 Evaluating the Prognostic Value of the Status Epilepticus Severity Score in Children
Speaker
Xinchi Li(China Pharmaceutical University)
P379 A Pharmacist-Led Study on Utilization Patterns of Paliperidone in Polypharmacy Patients
P379 A Pharmacist-Led Study on Utilization Patterns of Paliperidone in Polypharmacy Patients
Speaker
Manohar S K(JSS College of Pharmacy)
P380 An Ecological study on Polypharmacy and Dementia using NDB open data Japan
P380 An Ecological study on Polypharmacy and Dementia using NDB open data Japan
Speaker
NAOKO USHIDA(Teikyo University Graduate School of Public Health)
P381 Associations of polypharmacy with oral microbiome in US middle-aged and older adults
P381 Associations of polypharmacy with oral microbiome in US middle-aged and older adults
Speaker
Kai Wei(Guizhou Provincial People's Hospital)
P382 Cardiovascular related polypharmacy and its association with liver and kidney function
P382 Cardiovascular related polypharmacy and its association with liver and kidney function
Speaker
Caroline Trin(Monash University)
P383 Access to Contraceptives and Abortion Medications in High Income and LMICs
P383 Access to Contraceptives and Abortion Medications in High Income and LMICs
Speaker
Dima M Qato(University of Southern California)
P384 Evaluation of the Pregnancy Safety Information of Antineoplastic: The SFDA Experience
P384 Evaluation of the Pregnancy Safety Information of Antineoplastic: The SFDA Experience
Speaker
Manal Alrohaimi(Saudi Food and Drug Authority)
P385 Impact of severe maternal morbidity on perinatal outcomes in the United States
P385 Impact of severe maternal morbidity on perinatal outcomes in the United States
Speaker
QI LU(Shanghai Jiao Tong University)
P386 Infertility-Associated Psychological Stress: Optimizing FertiQoL Threshold Using Machine Learning Versus Biostatistical Models
P386 Infertility-Associated Psychological Stress: Optimizing FertiQoL Threshold Using Machine Learning Versus Biostatistical Models
Speaker
Lee Yu-Hsuan(National Cheng Kung University)
P387 Inhaled corticosteroids and long-acting beta2-agonists use during pregnancy and adverse fetal outcomes
P387 Inhaled corticosteroids and long-acting beta2-agonists use during pregnancy and adverse fetal outcomes
Speaker
Yea-Chwen Wu(National Taiwan University Hospital)
P388 Maternal and Neonatal Adverse Events of Oral Anti-hypertensives in Pregnancy: Disproportionality Analysis
P388 Maternal and Neonatal Adverse Events of Oral Anti-hypertensives in Pregnancy: Disproportionality Analysis
Speaker
Christy Thomas(National Institute of Pharmaceutical Education and Research)
P389 ORAL ANTI-HYPERTENSIVES IN THE TREATMENT OF PREECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
P389 ORAL ANTI-HYPERTENSIVES IN THE TREATMENT OF PREECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Speaker
Chippy Anna Joy(National Institute of Pharmaceutical Education and Research)
P390 Rheumatoid arthritis medications through before pregnancy and after delivery: JMDC Claims database
P390 Rheumatoid arthritis medications through before pregnancy and after delivery: JMDC Claims database
Speaker
Yuichi Shiotsuki(Keio university)
P391 Safety of omalizumab use during pregnancy on neonatal outcomes
P391 Safety of omalizumab use during pregnancy on neonatal outcomes
Speaker
Chung Hsuen Wu(Taipei Medical University)
P392 SYSTEMATIC REVIEW OF CHINESE EPIDEMIOLOGY AND RISK FACTORS OF ADVERSE PREGNANCY OUTCOMES
P392 SYSTEMATIC REVIEW OF CHINESE EPIDEMIOLOGY AND RISK FACTORS OF ADVERSE PREGNANCY OUTCOMES
Speaker
YANG Feng(Xiamen Chazen Biomedical technology Co., Ltd.)
Poster 2
Poster in Venue Ito: P188~P249
Poster in Venue Ito: P188~P249
Details
Date
October Sun 13, 2024 08:00 - 18:00
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Poster 2)
Chairperson
P188 Evaluation of the ADR Reporting System at a South Indian Teaching Hospital
P188 Evaluation of the ADR Reporting System at a South Indian Teaching Hospital
Speaker
RAMESH ADEPU(Vikas College of Pharmaceutical Sciences)
P189 Adverse reaction signal mining of off-label use of immune checkpoint inhibitors based on the FAERS database
P189 Adverse reaction signal mining of off-label use of immune checkpoint inhibitors based on the FAERS database
Speaker
Jiaxin Cai(University of Nottingham Ningbo China)
P190 Assessment of Drug Information Resources for Recommendations on Renal Drug Dosage Adjustment
P190 Assessment of Drug Information Resources for Recommendations on Renal Drug Dosage Adjustment
Speaker
Atiqulla Shariff(JSS College of Pharmacy, Mysuru)
P191 Bruton Tyrosine Kinase Inhibitors and Potential Risk of Drug-Induced Liver Injury
P191 Bruton Tyrosine Kinase Inhibitors and Potential Risk of Drug-Induced Liver Injury
Speaker
Waad Altayyar(saudi food and drug authority)
P193 Comparative Review: Overseas Safety Information Utilization in Japan, Australia, and the EU
P193 Comparative Review: Overseas Safety Information Utilization in Japan, Australia, and the EU
Speaker
Yeh Hyun Kim(Ewha Womans University)
P194 Corticosteroid Adverse Effects: A Comprehensive Study on Occurrence, Severity, and Preventability
P194 Corticosteroid Adverse Effects: A Comprehensive Study on Occurrence, Severity, and Preventability
Speaker
Jeesa George(Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences)
P195 Determine the Nature, Pattern, and Rate of Adverse Drug Reactions among Patients of Tertiary Care Hospital
P195 Determine the Nature, Pattern, and Rate of Adverse Drug Reactions among Patients of Tertiary Care Hospital
Speaker
Aman Haris(JSS College Of Pharmacy, Mysuru)
P196 Evaluation of medication safety program in ambulatory patients with chronic disease
P196 Evaluation of medication safety program in ambulatory patients with chronic disease
Speaker
RAVINDRA P CHOUDHARY(JSS COLLEGE OF PHARMACY)
P197 EXPLORING DRUG INTERACTIONS IN A HEMATOPOIETIC CELL TRANSPLANT UNIT: A COMPREHENSIVE ANALYSIS
P197 EXPLORING DRUG INTERACTIONS IN A HEMATOPOIETIC CELL TRANSPLANT UNIT: A COMPREHENSIVE ANALYSIS
Speaker
LITTY K(MS RAMAIAH UNIVERSITY OF APPLIED SCIENCES)
P198 Omeprazole and Potential Risk of Erectile Dysfunction
P198 Omeprazole and Potential Risk of Erectile Dysfunction
Speaker
Solaiman Alhawas(SFDA)
P199 Polypharmacy was positive associated with inflammatory makers in US older adults
P199 Polypharmacy was positive associated with inflammatory makers in US older adults
Speaker
chun chen(Guizhou Provincial People's Hospital)
P200 Pulmonary Events Associated with Proteasome Inhibitors: Quantitative Signal Detection Using FAERS Database
P200 Pulmonary Events Associated with Proteasome Inhibitors: Quantitative Signal Detection Using FAERS Database
Speaker
Muhammed Favas KT(National Institute of Pharmaceutical Education and Research)
P201 Risk of Drug-drug Interaction in Gout Arthritis Patients Prescribed NSAIDs
P201 Risk of Drug-drug Interaction in Gout Arthritis Patients Prescribed NSAIDs
Speaker
Mohammad Bakhriansyah(Universitas Lambung Mangkurat)
P202 Risk of Fracture Associated with Pregabalin or Mirogabalin Use: A Case-Case-Time-Control Study
P202 Risk of Fracture Associated with Pregabalin or Mirogabalin Use: A Case-Case-Time-Control Study
Speaker
Hinako Wakabayashi(Graduate School of Medicine and Public Health, Kyoto University)
P206 Extra labeled use Among Pet Owners: Insights from Saudi Arabia
P206 Extra labeled use Among Pet Owners: Insights from Saudi Arabia
Speaker
Jisha Myalil Lucca(Gulf medical University)
P207 Impact of Clinical Pharmacist Counselling on Medication Adherence among Cognitively Impaired Geriatrics
P207 Impact of Clinical Pharmacist Counselling on Medication Adherence among Cognitively Impaired Geriatrics
Speaker
Varsha N K(JSS COLLEGE OF PHARMACY,MYSURU,KA,INDIA)
P208 Prescription status of centrally acting muscle relaxants in Korean elderly
P208 Prescription status of centrally acting muscle relaxants in Korean elderly
Speaker
Dayeon Kim(Korea Institute of Drug Safety & Risk Management)
P209 Prevalence and Patterns of Drug-Related Problems Among Elderly Patients in Critical-Care Units
P209 Prevalence and Patterns of Drug-Related Problems Among Elderly Patients in Critical-Care Units
Speaker
SRUTHY JOSE(Jss College Of Pharmacy Mysore)
P210 Usage trends of government-subsidised cancer drugs in Australia: an analysis
P210 Usage trends of government-subsidised cancer drugs in Australia: an analysis
Speaker
Jasmine Lee(The University of Sydney)
P211 Development of Claim-Based Frailty Index in A Nationwide Database
P211 Development of Claim-Based Frailty Index in A Nationwide Database
Speaker
Shu Ping Huang(Changhua Christian Hospital)
P212 End-of-life medication management: A Delphi consensus approach in the Western Pacific region
P212 End-of-life medication management: A Delphi consensus approach in the Western Pacific region
Speaker
Xin Er Yaw(Monash University Malaysia)
P213 Potential drug-drug interactions in geriatric outpatients with depression in China
P213 Potential drug-drug interactions in geriatric outpatients with depression in China
Speaker
Hui Zhou(The First Affiliated Hospital of Xi’an Jiaotong University)
P214 Prevalence and risk factors of potentially inappropriate medication use in older Australians.
P214 Prevalence and risk factors of potentially inappropriate medication use in older Australians.
Speaker
Edward Chun Yin Lau(The University of Sydney)
P215 Statin Therapy for Primary Prevention in Old and Very Old Adults
P215 Statin Therapy for Primary Prevention in Old and Very Old Adults
Speaker
Wanchun Xu(The University of Hong Kong)
P216 Geographic Variations in Nicotine Dependency Treatment Use in Japan
P216 Geographic Variations in Nicotine Dependency Treatment Use in Japan
Speaker
Keiko Asao(Kappa Medical K.K.)
P217 "Biopsychosocial Determinants of CLBP in Northern India: A Population-Based Cross-Sectional Analysis"
P217 "Biopsychosocial Determinants of CLBP in Northern India: A Population-Based Cross-Sectional Analysis"
Speaker
Saroj Kundan Bharti(NIPER Mohali)
P219 Community Pharmacists’ Health Screening Services: Knowledge, Attitudes, Practice and Barriers
P219 Community Pharmacists’ Health Screening Services: Knowledge, Attitudes, Practice and Barriers
Speaker
Sreedharan Nair(Manipal Academy of Higher Education)
P220 Comparison of Health Literacy Between Immigrants and Natives in Taiwan
P220 Comparison of Health Literacy Between Immigrants and Natives in Taiwan
Speaker
PEI YEN YEH(National Taiwan University)
P221 Enhancing Health Equity: Evaluating South Africa's CCMDD Programme
P221 Enhancing Health Equity: Evaluating South Africa's CCMDD Programme
Speaker
Maggie Munsamy(National Department of Health, South Africa)
P222 Exploring Healthcare Professionals’ Attitude and Perceptions Towards Digital Health Technologies: A Cross-sectional Study
P222 Exploring Healthcare Professionals’ Attitude and Perceptions Towards Digital Health Technologies: A Cross-sectional Study
Speaker
Gangadharappa HV(JSS Academy of Higher Education and Research)
P223 Exploring Pharmacoepidemiology for Advancing Rare Diseases and Orphan Drug Research: Indian Perspective
P223 Exploring Pharmacoepidemiology for Advancing Rare Diseases and Orphan Drug Research: Indian Perspective
Speaker
Sangita Mishra(JSS College of Pharmacy, Mysuru)
P224 Five-year comparison of biological product approvals in Indonesia and the United States
P224 Five-year comparison of biological product approvals in Indonesia and the United States
Speaker
Erna Kristin(Universitas Gadjah Mada)
P225 IMPACT OF AMBULATORY PHARMACIST-LED TELEPHONIC INTERVENTION ON PATIENT’S HEALTH-RELATED QUALITY OF LIFE
P225 IMPACT OF AMBULATORY PHARMACIST-LED TELEPHONIC INTERVENTION ON PATIENT’S HEALTH-RELATED QUALITY OF LIFE
Speaker
RAVINDRA P CHOUDHARY(JSS COLLEGE OF PHARMACY)
P226 IMPACT OF ONCO-CLINICAL PHARMACIST IN HEMATOLOGICAL MALIGNANCY CENTRE: A RE-AIM FRAMEWORK ANALYSIS
P226 IMPACT OF ONCO-CLINICAL PHARMACIST IN HEMATOLOGICAL MALIGNANCY CENTRE: A RE-AIM FRAMEWORK ANALYSIS
Speaker
LITTY K(MS RAMAIAH UNIVERSITY OF APPLIED SCIENCES)
P227 Implementation and assessment of the developed MEDSTIK Tool in community pharmacies
P227 Implementation and assessment of the developed MEDSTIK Tool in community pharmacies
Speaker
Meenakshitha Panyala(JSS College of Pharmacy, Mysuru)
P228 Implementation of deprescribing in psychiatry: A prospective interventional study
P228 Implementation of deprescribing in psychiatry: A prospective interventional study
Speaker
Srikanth Malavali Siddalingegowda(JSS College of Pharmacy, Mysuru)
P229 Improving Comprehension of Oncology Drug Related Issue after Pharmacist Education
P229 Improving Comprehension of Oncology Drug Related Issue after Pharmacist Education
Speaker
Pei Youan Hung(Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation)
P230 Promoting Materiovigilance: Empowering Community Pharmacists with Sensitization Initiatives
P230 Promoting Materiovigilance: Empowering Community Pharmacists with Sensitization Initiatives
Speaker
Adusumilli Pramod Kumar(Ramaiah University of Applied Sciences)
P231 REAL WORLD EVIDENCE IN REGULATORY DECISION MAKING: CURRENT STATUS & FUTURE PROSPECTS
P231 REAL WORLD EVIDENCE IN REGULATORY DECISION MAKING: CURRENT STATUS & FUTURE PROSPECTS
Speaker
VENKATESH MADHUGIRI PRAKASH (JSS College of Pharmacy, Mysuru)
P232 Setting research-priorities for safe and rational use of medicines in Indian context
P232 Setting research-priorities for safe and rational use of medicines in Indian context
Speaker
SOWPARNIKA TREASA SABU(INDIAN COUNCIL OF MEDICAL RESEARCH (ICMR) Headquarters)
P233 Social media detoxification in pharmacy students: RCT study
P233 Social media detoxification in pharmacy students: RCT study
Speaker
Panida Horsiriluck(Faculty of Pharmacy, Chiang Mai University)
P234 Standardized Approach to Obtain Patients feedback on RMMs Shape and Content
P234 Standardized Approach to Obtain Patients feedback on RMMs Shape and Content
Speaker
Naser Aljaser(Saudi Food and Drug Authority)
P235 The context and perspectives for implementing a tailored pharmacist-led intervention in Indonesia
P235 The context and perspectives for implementing a tailored pharmacist-led intervention in Indonesia
Speaker
Indriastuti Cahyaningsih(Universitas Muhammadiyah Yogyakarta)
P238 A scoping review for Emulating a Target Trial in Vaccine
P238 A scoping review for Emulating a Target Trial in Vaccine
Speaker
Naohiro Yonemoto(University of Toyama)
P239 Distributed learning in effect estimation using routinely collected healthcare data:a systematic review
P239 Distributed learning in effect estimation using routinely collected healthcare data:a systematic review
Speaker
junting yang(peking university)
P240 Evaluation of time-related bias with non-user control
P240 Evaluation of time-related bias with non-user control
Speaker
Hiroya Morita(Tokyo Medical University)
P241 Lasso-type shrinkage method for the modified Poisson and least-squares regressions
P241 Lasso-type shrinkage method for the modified Poisson and least-squares regressions
Speaker
Takahiro Kitano(The Graduate University for Advanced Studies)
P242 Methods applied to assess real-world effectiveness of drugs: A scoping review
P242 Methods applied to assess real-world effectiveness of drugs: A scoping review
Speaker
Benedikte von Osmanski(Signum Life Science)
P243 Outlier detection and influence diagnostics for dose-response meta-analysis
P243 Outlier detection and influence diagnostics for dose-response meta-analysis
Speaker
Yamaguchi Kohei(The Graduate University for Advanced Studies)
P244 Exploring Methodologies to Incorporate Patient Voice in Pharmacoepidemiology Studies
P244 Exploring Methodologies to Incorporate Patient Voice in Pharmacoepidemiology Studies
Speaker
Yvonne Lee(IQVIA Solutions Asia)
P245 Characteristics of Duchenne Muscular Dystrophy Patients in Taiwan: A Population-Based Study
P245 Characteristics of Duchenne Muscular Dystrophy Patients in Taiwan: A Population-Based Study
Speaker
Hung-Wei Lin(IQVIA Solutions Taiwan)
P246 Epidemiological studies on the genetic background in the development of subacute myelo-optico-neuropathy
P246 Epidemiological studies on the genetic background in the development of subacute myelo-optico-neuropathy
Speaker
Hideki Matsumoto(Graduate School of Medicine, Gifu University)
P247 Riluzole use for motor neuron disease and all-cause mortality: A time-to-event analysis
P247 Riluzole use for motor neuron disease and all-cause mortality: A time-to-event analysis
Speaker
Min Fan(University of Hong Kong)
P248 Treatment patterns among patients with myasthenia gravis: An insurance claims database study
P248 Treatment patterns among patients with myasthenia gravis: An insurance claims database study
Speaker
Izumi Mishiro(UCB Japan Co., Ltd.)
P249 Valbenazine in Tardive Dyskinesia: Meta-analysis of RCTs and Retrospective Study of FAERS.
P249 Valbenazine in Tardive Dyskinesia: Meta-analysis of RCTs and Retrospective Study of FAERS.
Speaker
Beema T Yoosuf(National Institute of Pharmaceutical Education and Research)
P203 Study of adverse drug reactions and its clinical and economic implications of ADRs in Intensive Care Units.
P203 Study of adverse drug reactions and its clinical and economic implications of ADRs in Intensive Care Units.
Speaker
D S Sindoora(JSS College of Pharmacy, Mysuru)
P204 Trends in Adverse Drug Reactions in Ghana- Evidence of spontaneous reports, 2005-2021
P204 Trends in Adverse Drug Reactions in Ghana- Evidence of spontaneous reports, 2005-2021
Speaker
LINDA NYAME (Southeast University)
P205 Variation of Adverse Drug Events in Different Settings in Africa: Systematic Review
P205 Variation of Adverse Drug Events in Different Settings in Africa: Systematic Review
Speaker
LINDA NYAME (Southeast University)
P218 Assessment of new anti-cancer biological products approved through Priority Review in China
P218 Assessment of new anti-cancer biological products approved through Priority Review in China
Speaker
Pengcheng Liu(China Pharmaceutical University)
P236 The Impact of Volume-based Procurement on the Spatial Accessibility of Insulin
P236 The Impact of Volume-based Procurement on the Spatial Accessibility of Insulin
Speaker
LU LU(China Pharmaceutical University)
P237 A Comparative Review of International Common Data Models for Vaccine Safety
P237 A Comparative Review of International Common Data Models for Vaccine Safety
Speaker
Yulin Wang(Peking University)
Poster 2
Poster in Venue Ito: P393~P451
Poster in Venue Ito: P393~P451
Details
Date
October Mon 14, 2024 08:00 - 18:00
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Poster 2)
Chairperson
P393 Psychotropic medicine consumption in 83 countries and regions between 2017 and 2022
P393 Psychotropic medicine consumption in 83 countries and regions between 2017 and 2022
Speaker
CAIGE HUANG(University of Hong Kong)
P394 ADHD Medication Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns
P394 ADHD Medication Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns
Speaker
Eunsun Lim(Ewha Womans University)
P395 Antidepressant Use for Patients with Depression and the Risk of Diabetes
P395 Antidepressant Use for Patients with Depression and the Risk of Diabetes
Speaker
Io Hasebe(Kyoto University Hospital)
P396 Aripiprazole versus Second-generation Antipsychotic Use in Schizophrenia and Risk of Cardiovascular Events
P396 Aripiprazole versus Second-generation Antipsychotic Use in Schizophrenia and Risk of Cardiovascular Events
Speaker
Kuan Ting Chou(Taipei Medical University)
P397 Assessing drug utilization in cognitive impairment among the elderly population- A hospital-based longitudinal study
P397 Assessing drug utilization in cognitive impairment among the elderly population- A hospital-based longitudinal study
Speaker
Jignasa Chiramana(JSS College of Pharmacy, Mysuru)
P398 Assessment of DRP associated with use of psychiatric medication among non-psychiatric patients
P398 Assessment of DRP associated with use of psychiatric medication among non-psychiatric patients
Speaker
Srikanth Malavali Siddalingegowda(Faculty, JSS College of Pharmacy, Mysuru, INDIA)
P399 Assessment of Caregiver Burden among Caregivers of the Cognitively Impaired Patients
P399 Assessment of Caregiver Burden among Caregivers of the Cognitively Impaired Patients
Speaker
Veerendra A G(JSS academy of higher education and research)
P400 Association between lithium use and stroke risk: nationwide self-controlled case series study
P400 Association between lithium use and stroke risk: nationwide self-controlled case series study
Speaker
Chen-Yi Yang(National Cheng Kung University)
P401 Association between Social Media Addiction and Impostor Syndrome among Undergraduate Students.
P401 Association between Social Media Addiction and Impostor Syndrome among Undergraduate Students.
Speaker
Wannisa Seangsanoah(Faculty of Pharmacy, Chiang Mai university)
P402 Association between the Use of Incretin-Based Therapies and the Risk of Depression
P402 Association between the Use of Incretin-Based Therapies and the Risk of Depression
Speaker
SHIH YU LIU(National Taiwan University)
P403 Association of road traffic injuries with gabapentinoid treatment: a self-controlled case-series study
P403 Association of road traffic injuries with gabapentinoid treatment: a self-controlled case-series study
Speaker
Siu Chung Andrew Yuen(UCL School of Pharmacy)
P404 Barriers and Influential Factors in Quitting/Reducing E-Cigarette Use Among University Students
P404 Barriers and Influential Factors in Quitting/Reducing E-Cigarette Use Among University Students
Speaker
Surarong Chinwong(Faculty of Pharmacy, Chiang Mai University)
P405 Burden of depressive disorders in Vietnam from 1990 to 2019
P405 Burden of depressive disorders in Vietnam from 1990 to 2019
Speaker
QUYNH THI VU(Okayama University)
P406 Clinical Spectrum and Management Challenges of Reflex Epilepsy: Insights from Northeast India
P406 Clinical Spectrum and Management Challenges of Reflex Epilepsy: Insights from Northeast India
Speaker
RUBY KASANA(NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH)
P407 Effect of drug utilization review on prescription of typical antipsychotics to elderly
P407 Effect of drug utilization review on prescription of typical antipsychotics to elderly
Speaker
SUJI OH(Korea Institute of Drug Safety & Risk Management)
P408 Evaluating LID Prevalence and Influencing Factors in PD Patients: A Pharmacovigilance Study
P408 Evaluating LID Prevalence and Influencing Factors in PD Patients: A Pharmacovigilance Study
Speaker
AKANKSHA LAHIRI(JSS College of Pharmacy, JSSAHER, Mysuru)
P409 Evaluations of Mental Health Conditions among Children with and without Diabetes.
P409 Evaluations of Mental Health Conditions among Children with and without Diabetes.
Speaker
Ching Yi Su(TMU)
P410 Haematological malignancy following clozapine or olanzapine use in schizophrenia: retrospective cohort study
P410 Haematological malignancy following clozapine or olanzapine use in schizophrenia: retrospective cohort study
Speaker
Yuqi HU(the University of Hong Kong)
P411 HbA1c Recording in Patients with Schizophrenia or Bipolar Disorder in DATuM IDEA®
P411 HbA1c Recording in Patients with Schizophrenia or Bipolar Disorder in DATuM IDEA®
Speaker
Nobuo Mochizuki(TOPPAN Holdings Inc.)
P412 Medication Use Evaluation of ADHD Treatment at a Medical Center
P412 Medication Use Evaluation of ADHD Treatment at a Medical Center
Speaker
Lu-Hsuan Wu(National Cheng Kung University Hospital)
P413 Persistence and Adherence of ADHD Medications in Japanese patients
P413 Persistence and Adherence of ADHD Medications in Japanese patients
Speaker
Atsushi Urano(keio university)
P414 Pharmacists’ Knowledge, Attitudes, Perceived barriers on providing medication counseling to psychiatric patients
P414 Pharmacists’ Knowledge, Attitudes, Perceived barriers on providing medication counseling to psychiatric patients
Speaker
Wijemuni Ishara Gayani De Silva(General Sir John Kotelawala Defence University)
P415 Real-world Persistence and Adherence of Paliperidone in Adolescent Schizophrenia Patients in China
P415 Real-world Persistence and Adherence of Paliperidone in Adolescent Schizophrenia Patients in China
Speaker
Sijia Dong(Johnson & Johnson)
P416 Risks assessment of antiseizure medications related Parkinson’s disease between valproate and levetiracetam in adults with seizure
P416 Risks assessment of antiseizure medications related Parkinson’s disease between valproate and levetiracetam in adults with seizure
Speaker
Yu-Rou Jiang(National Taiwan University)
P417 Social media addiction and behavior of social media usage in undergraduate students
P417 Social media addiction and behavior of social media usage in undergraduate students
Speaker
Chanapa Yangmang(Faculty of Pharmacy, Chiang Mai University)
P418 The Impact of Winter on the Use of Antidepressants
P418 The Impact of Winter on the Use of Antidepressants
Speaker
LU LU(China Pharmaceutical University)
P419 The Interconnection Between Depression and Chronic Kidney Disease.
P419 The Interconnection Between Depression and Chronic Kidney Disease.
Speaker
Kan-Chih Chen(TMU)
P420 The role of antipsychotics on associations between extreme temperature and heat-related outcomes
P420 The role of antipsychotics on associations between extreme temperature and heat-related outcomes
Speaker
Zixuan Wang(London School of Hygiene and Tropical Medicine)
P421 Trajectories of risperidone use for changed behaviours in people with Alzheimer’s disease: a nationwide study
P421 Trajectories of risperidone use for changed behaviours in people with Alzheimer’s disease: a nationwide study
Speaker
Danika Davis(Centre of Medicines Use and Safety, Monash University)
P422 Umbrella Review on First-Line Therapy Options for Infantile Epileptic Spasms Syndrome
P422 Umbrella Review on First-Line Therapy Options for Infantile Epileptic Spasms Syndrome
Speaker
Saroj Kundan Bharti(NIPER Mohali)
P423 ADHD medication use and cardiometabolic conditions in pregnancy: A population-based cohort study
P423 ADHD medication use and cardiometabolic conditions in pregnancy: A population-based cohort study
Speaker
Masako Araki(UNSW Sydney)
P424 Assessment of Real-World Data Sources and A Hybrid Approach in Evidence Generation
P424 Assessment of Real-World Data Sources and A Hybrid Approach in Evidence Generation
Speaker
Yvonne Lee(IQVIA Solutions Asia)
P425 Bias description among pharmacoepidemiologic studies applying common data model: a systematic review
P425 Bias description among pharmacoepidemiologic studies applying common data model: a systematic review
Speaker
YONGQI ZHENG(Peking University)
P426 Examination of methods for utilizing unstructured data using "Millennial Medical Record"
P426 Examination of methods for utilizing unstructured data using "Millennial Medical Record"
Speaker
Mako Furukawa(Shionogi & Co., Ltd)
P427 The use of real-world evidence in Japan cost effectiveness analyses
P427 The use of real-world evidence in Japan cost effectiveness analyses
Speaker
zhihong cai(Eli Lilly Japan)
P428 Elevated Respiratory Complications following Robotic-Assisted Lobectomy: A National Cohort Analysis
P428 Elevated Respiratory Complications following Robotic-Assisted Lobectomy: A National Cohort Analysis
Speaker
Ruijian Huang(China Pharmaceutical University)
P429 Evaluating In-Hospital Outcomes of the Ross Procedure Using Real-World Data
P429 Evaluating In-Hospital Outcomes of the Ross Procedure Using Real-World Data
Speaker
Jifang Zhou(China Pharmaceutical University)
P430 Intraoperative Hemodynamics and Postoperative Outcomes in Type A Aortic Dissection
P430 Intraoperative Hemodynamics and Postoperative Outcomes in Type A Aortic Dissection
Speaker
Jifang Zhou(China Pharmaceutical University)
P431 Active surveillance of medical device associated adverse events at tertiary care hospital
P431 Active surveillance of medical device associated adverse events at tertiary care hospital
Speaker
Gangadharappa HV(JSS Academy of Higher Education and Research)
P433 Biological Age's Association with Postoperative Renal Outcomes After Surgery
P433 Biological Age's Association with Postoperative Renal Outcomes After Surgery
Speaker
Xinchi Li(China Pharmaceutical University)
P434 INVESTIGATING DRUG RELATED PROBLEMS IN PATIENTS FOLLOWING CARDIAC SURGERY: A PROSPECTIVE STUDY
P434 INVESTIGATING DRUG RELATED PROBLEMS IN PATIENTS FOLLOWING CARDIAC SURGERY: A PROSPECTIVE STUDY
Speaker
Mohamed Nisarahmed Esha (MS Ramaiah University of Applied Sciences)
P435 Predictive Modeling of Intraoperative Acquired Pressure Injuries
P435 Predictive Modeling of Intraoperative Acquired Pressure Injuries
Speaker
Jifang Zhou(China Pharmaceutical University)
P436 PREDICTORS OF POST-OPERATIVE COMPLICATIONS IN PATIENTS FOLLOWING CARDIAC SURGERY: A PROSPECTIVE STUDY
P436 PREDICTORS OF POST-OPERATIVE COMPLICATIONS IN PATIENTS FOLLOWING CARDIAC SURGERY: A PROSPECTIVE STUDY
Speaker
Mohamed Nisarahmed Esha (MS Ramaiah University of Applied Sciences)
P437 Sex-specific Roles of Early-postoperative Hemoglobin on Adverse Kidney Outcomes After Cardiac Surgery
P437 Sex-specific Roles of Early-postoperative Hemoglobin on Adverse Kidney Outcomes After Cardiac Surgery
Speaker
Siyu Kong(China Pharmaceutical University)
P438 The Influence of Timing in Cholecystectomy on the Incidence of Post-ERCP Pancreatitis
P438 The Influence of Timing in Cholecystectomy on the Incidence of Post-ERCP Pancreatitis
Speaker
RATHOD MAHESH(National institute of pharmaceutical education and research)
P443 Design and Analytical Methods for Vaccine Safety Evaluation
P443 Design and Analytical Methods for Vaccine Safety Evaluation
Speaker
Yukari Uemura(NCGM)
P444 Exploring determinants of human papillomavirus vaccination initiation and completion among adult females
P444 Exploring determinants of human papillomavirus vaccination initiation and completion among adult females
Speaker
George Okoli(The University of Hong Kong)
P446 Impact of the universal seasonal influenza vaccination policy in Manitoba, Canada
P446 Impact of the universal seasonal influenza vaccination policy in Manitoba, Canada
Speaker
George Okoli(The University of Hong Kong)
P447 Individual characteristics associated with adherence to seasonal influenza vaccination in Manitoba, Canada
P447 Individual characteristics associated with adherence to seasonal influenza vaccination in Manitoba, Canada
Speaker
George Okoli(The University of Hong Kong)
P448 Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza among Chinese elderly
P448 Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza among Chinese elderly
Speaker
Jifang Zhou(China Pharmaceutical University)
P449 Repeated vaccination and protective effect of influenza vaccine in the elderly
P449 Repeated vaccination and protective effect of influenza vaccine in the elderly
Speaker
Jifang Zhou(China Pharmaceutical University)
P450 Validation of COPD Severity According to the GOLD Framework in Claims Database
P450 Validation of COPD Severity According to the GOLD Framework in Claims Database
Speaker
Ju-Ling Chen(National Cheng Kung University Hospital)
P445 Hepatitis B vaccine safety: Analysis of adverse reactions based on VAERS database
P445 Hepatitis B vaccine safety: Analysis of adverse reactions based on VAERS database
Speaker
Pengcheng Liu(China Pharmaceutical University)
P451 Validation of ICD-CM codes to identify relapsed metastatic breast cancer in Taiwan
P451 Validation of ICD-CM codes to identify relapsed metastatic breast cancer in Taiwan
Speaker
Yan Lin Wang(Department of Pharmacy, Linkou Chang Gung Memorial Hospital)
Spotlight Poster 1
Poster in Venue Ito: P500~P514
Poster in Venue Ito: P500~P514
Details
Date
October Sun 13, 2024 08:00 - 18:00
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Spotlight Poster)
Chairperson
SP500 Optimizing Depression Treatment: A Cost-Effectiveness Analysis of Pharmacogenetic-Guided Therapy in Qatar
SP500 Optimizing Depression Treatment: A Cost-Effectiveness Analysis of Pharmacogenetic-Guided Therapy in Qatar
Speaker
Daoud Al-Badriyeh(QATAR UNIVERSITY)
SP501 Exploring Glucocorticoid Receptor Expression in Type 2 Diabetes Mellitus Sepsis Patients
SP501 Exploring Glucocorticoid Receptor Expression in Type 2 Diabetes Mellitus Sepsis Patients
Speaker
Gestina Aliska(Faculty of Medicine, Universitas Andalas)
SP502 Comparison of machine learning models on cardiovascular risk prediction in diabetic patients
SP502 Comparison of machine learning models on cardiovascular risk prediction in diabetic patients
Speaker
Kiyoshi Minematsu(EPS Corporation)
SP504 Long term Comparative Safety of ARNi verses ACEi/ARB: A Real-World Data analysis
SP504 Long term Comparative Safety of ARNi verses ACEi/ARB: A Real-World Data analysis
Speaker
Yasmin Elsobky(ALNAS Hospital)
SP505 Antibiotic use in Singapore pre- and post-COVID-19: a quasi-experimental approach
SP505 Antibiotic use in Singapore pre- and post-COVID-19: a quasi-experimental approach
Speaker
Shi Thong Heng(MOH)
SP506 Association between SGLT2 inhibitor exposure and risk of gastroesophageal reflux disease
SP506 Association between SGLT2 inhibitor exposure and risk of gastroesophageal reflux disease
Speaker
Ting Yu Jian(National Taiwan University)
SP507 Association Between Metabolic Syndrome And Chronic Periodontitis in Japanese Claims Database
SP507 Association Between Metabolic Syndrome And Chronic Periodontitis in Japanese Claims Database
Speaker
Makoto KANENISHI(Ark Medical Solutions Inc.)
SP508 Treatment Patterns of Patients with Rheumatoid Arthritis in Japanese Claims Database
SP508 Treatment Patterns of Patients with Rheumatoid Arthritis in Japanese Claims Database
Speaker
Masaru Koyama(Ark Medical Solutions Inc.)
SP509 Drug Utilization Pattern of Anticholinergic Drugs among Patients with Dementia in Taiwan
SP509 Drug Utilization Pattern of Anticholinergic Drugs among Patients with Dementia in Taiwan
Speaker
YU-HSUAN KUO(Taipei Medical University)
SP510 Reassessment and update of the Japanese Treatment Satisfaction Questionnaire for Medication (TSQM)
SP510 Reassessment and update of the Japanese Treatment Satisfaction Questionnaire for Medication (TSQM)
Speaker
Anzu Yakushiji(IQVIA Solutions Japan G.K.)
SP511 Myasthenia gravis following initiation of statin therapy: multinational self-controlled case series study
SP511 Myasthenia gravis following initiation of statin therapy: multinational self-controlled case series study
Speaker
Vincent Ka Chun Yan(The University of Hong Kong)
SP512 Association between SGLT-2 inhibitors and DPP4-inhibitors Use and Risk of Acute Pancreatitis
SP512 Association between SGLT-2 inhibitors and DPP4-inhibitors Use and Risk of Acute Pancreatitis
Speaker
YEJEE KIM(Asan Medical Center)
SP513 Effectiveness and Safety of First-line Chemotherapy in Elderly Metastatic Pancreatic Cancer Patients
SP513 Effectiveness and Safety of First-line Chemotherapy in Elderly Metastatic Pancreatic Cancer Patients
Speaker
Chin-Wei Hsu(Chi Mei Medical Center)
SP514 Gender Differences in Safety of Polypharmacy in Korean Elderly
SP514 Gender Differences in Safety of Polypharmacy in Korean Elderly
Speaker
Heehyun Won(College of Science and Industry Convergence)
Spotlight Poster 2
Poster in Venue Ito: P515~P529
Poster in Venue Ito: P515~P529
Details
Date
October Mon 14, 2024 08:00 - 18:00
Room
Ito International Research Centre (Venue Ito)(The University of Tokyo (Hongo Campus) Spotlight Poster)
Chairperson
SP515 Performance status classification of lung cancer patients by trained machine leaning
SP515 Performance status classification of lung cancer patients by trained machine leaning
Speaker
Shunsuke Takada(Daiichi Sankyo Co., Ltd.)
SP517 Identification of Hypocalcemia Prognostic Factors with Romosozumab Administration: A Nested Case-Control Study
SP517 Identification of Hypocalcemia Prognostic Factors with Romosozumab Administration: A Nested Case-Control Study
Speaker
Hui-Ni Huang(LinKou Chang Gung Memorial Hospital)
SP518 Lithium and risk of fractures in bipolar disorder: A Population-Based Cohort Study
SP518 Lithium and risk of fractures in bipolar disorder: A Population-Based Cohort Study
Speaker
Vanessa Ng(The University of Hong Kong)
SP519 Comparative effectiveness of long-acting injectable versus oral antipsychotics in patients with schizophrenia
SP519 Comparative effectiveness of long-acting injectable versus oral antipsychotics in patients with schizophrenia
Speaker
Yusuke Okada(Keio University)
SP520 Quantification and Related Factors of Oversupply of Chronic Disease Medications in Japan.
SP520 Quantification and Related Factors of Oversupply of Chronic Disease Medications in Japan.
Speaker
Junko Tomida(Tokushima Bunri University)
SP521 Telomere length, a marker of aging, based on nutritional status in women
SP521 Telomere length, a marker of aging, based on nutritional status in women
Speaker
Desmawati Desmawati(Universitas Andalas)
SP522 Validation of claims-based algorithms for intussusception in Japan: The CLEAR Study
SP522 Validation of claims-based algorithms for intussusception in Japan: The CLEAR Study
Speaker
Ishiguro Chieko(National Center for Global Health and Medicine)
SP523 A Prediction Model for the 5-ASA Intolerance among Japanese ulcerative colitis patients
SP523 A Prediction Model for the 5-ASA Intolerance among Japanese ulcerative colitis patients
Speaker
Kazuto Koshiro(Kyoto Prefectural University of Medicine)
SP524 Erythropoiesis-stimulating agents and osteoporotic fracture in chronic kidney disease: A case-control study
SP524 Erythropoiesis-stimulating agents and osteoporotic fracture in chronic kidney disease: A case-control study
Speaker
Suhas Krishnamoorthy(The University of Hong Kong)
SP525 Exploring Signals of Substance Use Disorder Using VigiBase
SP525 Exploring Signals of Substance Use Disorder Using VigiBase
Speaker
Ju Won Lee(Chung-Ang University)
SP526 Pharmacoepidemiology of Tuberculosis Preventive Therapy in HIV Programs in Nigeria: Lessons Learned
SP526 Pharmacoepidemiology of Tuberculosis Preventive Therapy in HIV Programs in Nigeria: Lessons Learned
Speaker
Ozioma Onokala(AIDS Healthcare Foundation Nigeria)
SP527 Antibiotic utilization in infective endocarditis management at a teaching hospital in Vietnam
SP527 Antibiotic utilization in infective endocarditis management at a teaching hospital in Vietnam
Speaker
Thi Lan Nhi Vu(University Medical Center Ho Chi Minh City)
SP516 Comparative Effectiveness of Levetiracetam versus Valproic Acid in Post-Stroke Seizure Patients
SP516 Comparative Effectiveness of Levetiracetam versus Valproic Acid in Post-Stroke Seizure Patients
Speaker
Chi-Chuan Wang(National Taiwan University)
SP528 Von Hippel-Lindau disease-associated renal cell carcinoma natural history study in China
SP528 Von Hippel-Lindau disease-associated renal cell carcinoma natural history study in China
Speaker
Jiahuang Lin(MSD R&D China)
SP529 Efficacy and safety of parpi as 1l-maintenance therapy in aoc: network meta-analysis
SP529 Efficacy and safety of parpi as 1l-maintenance therapy in aoc: network meta-analysis
Speaker
Saurabh Wadghule(National Institute of Pharmaceutical Education and Research)
TRACK A
Designing pharmacoepidemiologic studies from clinical questions
Designing pharmacoepidemiologic studies from clinical questions
Details
Date
October Sat 12, 2024 09:10 - 09:40
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Track A)
Chairperson
　 Designing pharmacoepidemiologic studies from clinical questions
　 Designing pharmacoepidemiologic studies from clinical questions
Speaker
Esther Chan(HKU)
TRACK A
Principles of pharmacoepidemiology using large databases
Principles of pharmacoepidemiology using large databases
Details
Date
October Sat 12, 2024 09:40 - 11:10
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Track A)
Chairperson
　 Principles of pharmacoepidemiology using large databases
　 Principles of pharmacoepidemiology using large databases
Speaker
Juliana de Oliveira Costa( UNSW)
TRACK A
Evaluation of clinical outcomes in healthcare databases
Evaluation of clinical outcomes in healthcare databases
Details
Date
October Sat 12, 2024 11:40 - 13:10
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Track A)
Chairperson
　 Evaluation of clinical outcomes in healthcare databases
　 Evaluation of clinical outcomes in healthcare databases
Speaker
Shirley Li(Hong Kong University )
TRACK A
Practical skills in protocol writing and statistical analytic programming in pharmacoepidemiology 1
Practical skills in protocol writing and statistical analytic programming in pharmacoepidemiology 1
Details
Date
October Sat 12, 2024 14:10 - 15:40
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Track A)
Chairperson
　 Practical skills in protocol writing and statistical analytic programming in
pharmacoepidemiology- From Research Question to Protocol
　 Practical skills in protocol writing and statistical analytic programming in
pharmacoepidemiology- From Research Question to Protocol
Speaker
Ben Daniels(UNSW)
TRACK A
Practical skills in protocol writing and statistical analytic programming in pharmacoepidemiology 2
Practical skills in protocol writing and statistical analytic programming in pharmacoepidemiology 2
Details
Date
October Sat 12, 2024 16:10 - 17:30
Room
Sanjo Conference Hall (Venue S)(The University of Tokyo (Hongo Campus) Track A)
Chairperson
　 Practical skills in protocol writing and statistical analytic programming in
pharmacoepidemiology – From Protocol to SAS Programming
　 Practical skills in protocol writing and statistical analytic programming in
pharmacoepidemiology – From Protocol to SAS Programming
Speaker
Steven Chin-Yao Shen(NCKU)
TRACK B
Selection of medical information databases
Selection of medical information databases
Details
Date
October Sat 12, 2024 08:30 - 09:30
Room
Takeda Bldg. (Venue T)(The University of Tokyo (Hongo Campus) Takeda Bldg. (Venue T))
Chairperson
　 Selection of medical information databases
　 Selection of medical information databases
Speaker
Yasunari Sadatsuki(Bayer Yakuhin, Ltd. )
TRACK B
Common study designs in pharmacoepidemiology studies
Common study designs in pharmacoepidemiology studies
Details
Date
October Sat 12, 2024 09:45 - 10:45
Room
Takeda Bldg. (Venue T)(The University of Tokyo (Hongo Campus) Takeda Bldg. (Venue T))
Chairperson
　 Common study designs in pharmacoepidemiology studies
　 Common study designs in pharmacoepidemiology studies
Speaker
Wataru Mimura(National Center for Global Health and Medicine)
TRACK B
Common biases in pharmacoepidemiology
Common biases in pharmacoepidemiology
Details
Date
October Sat 12, 2024 11:00 - 12:00
Room
Takeda Bldg. (Venue T)(The University of Tokyo (Hongo Campus) Takeda Bldg. (Venue T))
Chairperson
　 Common biases in pharmacoepidemiology
　 Common biases in pharmacoepidemiology
Speaker
Motohiko Adomi(Harvard University)
TRACK B
Causal interpretation of hazard ratio
Causal interpretation of hazard ratio
Details
Date
October Sat 12, 2024 13:10 - 14:10
Room
Takeda Bldg. (Venue T)(The University of Tokyo (Hongo Campus) Takeda Bldg. (Venue T))
Chairperson
　 Causal interpretation of hazard ratio
　 Causal interpretation of hazard ratio
Speaker
Tomohiro Shinozaki(Tokyo University of Science)
TRACK B
Time-varying treatment and confounder
Time-varying treatment and confounder
Details
Date
October Sat 12, 2024 14:10 - 15:10
Room
Takeda Bldg. (Venue T)(The University of Tokyo (Hongo Campus) Takeda Bldg. (Venue T))
Chairperson
　 Time-varying treatment and confounder
　 Time-varying treatment and confounder
Speaker
Yasuhiro Hagiwara(The University of Tokyo)
TRACK B
Causal inference based on self-controlled study designs
Causal inference based on self-controlled study designs
Details
Date
October Sat 12, 2024 15:30 - 16:30
Room
Takeda Bldg. (Venue T)(The University of Tokyo (Hongo Campus) Takeda Bldg. (Venue T))
Chairperson
　 Causal inference based on self-controlled study designs
　 Causal inference based on self-controlled study designs
Speaker
Yoshinori Takeuchi(Yokohama City University)
TRACK B
Missing data analyses
Missing data analyses
Details
Date
October Sat 12, 2024 16:30 - 17:30
Room
Takeda Bldg. (Venue T)(The University of Tokyo (Hongo Campus) Takeda Bldg. (Venue T))
Chairperson
　 Missing data analyses
　 Missing data analyses
Speaker
Aya Kuchiba(Teikyo University)
TRACK D
PE guidance in transparency, and reproducibility in Europe, US and Asia
PE guidance in transparency, and reproducibility in Europe, US and Asia
Details
Date
October Sat 12, 2024 08:30 - 10:00
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
　 PE guidance in transparency, and reproducibility in Europe, US and Asia
　 PE guidance in transparency, and reproducibility in Europe, US and Asia
Speaker
Olaf Klungel(Utrecht University)
TRACK D
Methods for Validation Study for clinical endpoints
Methods for Validation Study for clinical endpoints
Details
Date
October Sat 12, 2024 10:30 - 12:00
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
　 Methods for Validation Study for clinical endpoints
　 Methods for Validation Study for clinical endpoints
Speaker
Takuhiro Yamaguchi(Tohoku University)
TRACK D
Advanced topics for the target trial emulation
Advanced topics for the target trial emulation
Details
Date
October Sat 12, 2024 13:00 - 14:30
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
　 Advanced topics for the target trial emulation
　 Advanced topics for the target trial emulation
Speaker
Edward Lai(National Cheng Kung University)
TRACK D
Prevalent New User Design: Considerations, Challenges, and Opportunities
Prevalent New User Design: Considerations, Challenges, and Opportunities
Details
Date
October Sat 12, 2024 15:00 - 16:00
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
　 Prevalent New User Design: Considerations, Challenges, and Opportunities
　 Prevalent New User Design: Considerations, Challenges, and Opportunities
Speaker
Kristian B Filion(McGill University)
TRACK D
Methods in Environmental Pharmacoepidemiology
Methods in Environmental Pharmacoepidemiology
Details
Date
October Sat 12, 2024 16:20 - 17:30
Room
Yasuda Auditorium (Venue Y)(The University of Tokyo (Hongo Campus) Room 1)
Chairperson
　 　
　 　
Speaker
Benjamin Bates(Rutgers University)
TOP